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Guidance on the Administration to Adults of Oil-based Depot and 
other Long-Acting Intramuscular Antipsychotic Injections. 
 
 
Appendix 1 of this document contains Six Standard 
Operating Procedures (SOPs) for the administration to adults of 
oil-based depot and other long-acting antipsychotic injections: 




SOP 1.    General Preparation for Deep Intramuscular 
               (IM) Injection 
 
SOP 2.    Z-track Administration Technique 
 
SOP 3.    Deltoid Administration Technique  
 
SOP 4.    Dorsogluteal Administration Technique  
 
SOP 5.    Ventrogluteal Administration Technique  
 
SOP 6.    Vastus Lateralis Administration Technique   
 
 
This document may be downloaded from the following websites: 
 
College of Mental Health Pharmacy  www.cmhp.org.uk 




How to reference this document: 
 
Feetam C. & White J. Guidance on the Administration to Adults of Oil-based Depot and 
other Long-Acting Intramuscular Antipsychotic Injections 6th Edition (2020) available at 
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1.1 Injection technique is traditionally based on practice which is underpinned by evidence from 
expert opinion and clinical experience. It is then disseminated by modelling the technique to 
subsequent generations of clinicians. This is a much lower level of evidence than that normally 
required to demonstrate the efficacy of an intervention or technique such as by a randomised 
controlled trial (RCT). The best quality evidence is obtained from primary research where 
rigorous methodological and ethical standards are applied to confirm or refute cause and effect. 
Within primary research the level of evidence varies from well-conducted and adequately 
powered RCTs to evidence from uncontrolled (naturalistic or observational) studies and/or 
published case reports or series. This guidance has been produced following an extensive and 
systematic review of the literature and provides references to the primary research where this 
is available. There is, however, a paucity of good-quality evidence for some of the issues 
considered and where this is the case this is reflected in the guidance. 
 
1.2 This guidance provides a flexible framework within which clinicians working for mental 
health service providers in the UK may consider their own clinical policies; it supports how these 
may be adapted locally to further enhance the safe administration of oil-based depot and other 
long-acting intramuscular antipsychotic injections. 
 
1.3 This guidance takes into account the requirement of the Care Quality Commission for 
clinicians to continue to provide evidence of safe practice in the care of their patients.1 
 
1.4 This guidance provides a framework for clinical quality standards in harmony with the 
provision of information for NHS Resolution,2 the Care Quality Commission1 and the pledges 
made by the NHS Constitution.3 
 
1.5 The framework is intended to enhance governance arrangements for upholding the 
professional code of practice of the Nursing and Midwifery Council (NMC),4 the professional 
guidance on the administration of medicines in healthcare settings by the Royal Pharmaceutical 
Society (RPS) and Royal College of Nursing (RCN),5 and the recommendations from the 
National Patient Safety Agency (NPSA, now NHS Improvement).6  
 
1.6 This guidance is intended to support culture change for safer patient care by providing 
information on service improvement that can be harnessed and used collectively in a 
coordinated way by organisations. It can be used as a catalyst for nurse leaders to inspire, 
prepare and equip nurses with defined technical skills and competencies for the procedure. 
 
    








This document is underpinned by the following principles: 
 
2.1 The need for clinical competence in order to reduce the risks associated with human error 
and provide safe care through systematic and meticulous practice. 
 
2.2 The requirement for a clinically driven national resource derived from the current evidence 
base to support local practitioners. This includes adherence to the principles of guidance from 
the NPSA (now NHS Improvement).6 
 
2.3 The opportunity to offer the experienced practitioner a flexible framework within which 
they may make appropriate clinical judgments. 
 
2.4 The need to manage the care of those with long-term conditions appropriately.  
 
2.5 The requirement to provide information that is accessible to patients and carers as well 
as to clinicians. 
 
2.6 The need to contribute to enhanced treatment choice, and the right of an individual to be 
offered a choice of antipsychotic and its formulation where alternatives exist. 
 
2.7 The recognition of an individual's right to be offered a choice of injection site for the 
administration of a long-acting intramuscular antipsychotic injection where the licence 
permits. 
 
2.8 The need to influence public perception and diminish notions of coercion and stigma 
associated with the use of such injections, particularly in the context of mental health 
legislation. 
  
2.9 The necessity to preserve the dignity of and respect for the patient, by the promotion of 





























3.1 Oil-based depot and other long-acting intramuscular antipsychotic injections are key 
interventions for a significant number of people in the recovery phase of a severe and 
enduring mental illness such as schizophrenia.7,8
 In 2009 it was reported that between 29% and 30% of patients with schizophrenia in the UK 
were prescribed a long-acting injectable antipsychotic.9
    
3.2 Long-acting antipsychotic injections should be considered for people with psychosis or 
schizophrenia who would prefer such a formulation after an acute episode or where avoiding 
covert non-adherence (either intentional or unintentional) to oral antipsychotic medicines is a 
clinical priority within the treatment plan.7,8  
 
3.3 First generation antipsychotics are more often associated with extrapyramidal side effects 
and a higher risk of tardive dyskinesia than second generation antipsychotics.7,8 This risk of 
adverse effects and the associated stigma have previously influenced treatment choice in favour 
of an oral second generation rather than a long-acting first generation formulation. The 
availability of long-acting intramuscular second-generation antipsychotic injections now means 
that choosing a long-acting intramuscular formulation does not automatically mean treatment 
with a first generation antipsychotic. 
 
3.4 Medicines optimisation is an individualised person-centred approach to the use of 
medicines that involves engaging with patients to get their medicines right for them. It ensures 
the best possible outcomes by minimising risk and maximising benefit using evidence-based 
decision making. It requires effective patient engagement and professional collaboration.10
 The treatment of schizophrenia may be optimised by:7,8  
• offering a choice of treatments 
• prescribing an effective, optimum dose for an appropriate period of time before 
considering a dose change or switch 
• providing adherence support regularly and frequently  
• offering a long-acting injectable antipsychotic  
• ensuring physical health is not compromised further  
 
3.5 The safe administration of oil-based depot and other long-acting intramuscular 
antipsychotic injections is an integral part of the work of registered practitioners in mental health 
and errors can be minimised through the application of a framework such as this guidance 
provides that identifies the technical competency required for all aspects of the procedure. 
 









4.1 Oil-based depot antipsychotic injections are all licensed to be given by deep intramuscular 
injection into the gluteal muscle at intervals of one to four weeks. Some (flupentixol and 
zuclopenthixol*) are also licensed to be given into the lateral thigh (vastus lateralis) (see 
Appendix 2). They all have a similar licensed indication, which is for the maintenance 
treatment of schizophrenia and other psychoses.11,12 
 
4.2 For these oil-based depot antipsychotic injections, a small test dose of the injection must 
be given before the full treatment schedule is initiated. This is to confirm tolerability to both 
the active ingredient as well as the oily vehicle, since any adverse effect will be prolonged.11,12 
 
4.3 Full details of test doses for the oil-based depot injections are given in each individual 
Summary of Product Characteristics (SmPC)11 and in the British National Formulary (BNF).12 
Treatment may normally be initiated four to seven days after a successful test dose.11,12 
 





Example: The test dose of fluphenazine decanoate for an adult is 12.5 mg.13 The 
smallest dose/volume available of fluphenazine decanoate is 0.5 ml ampoules 
containing 12.5 mg in 0.5 ml. The test dose for an adult is therefore  
0.5 ml. If, however, only the 25 mg in 1 ml ampoule was available, the test dose 










*See prescribing information for further details on both named products. 








5.1 Aripiprazole long-acting injection14 is licensed for the maintenance treatment of 
schizophrenia in adults stabilised with oral aripiprazole. It is presented as a polymer of 
aripiprazole monohydrate, a dry powder for reconstitution and suspension in the solvent 
supplied (water for injection). Separate vials containing the 300 mg and 400 mg doses are 
available. Pre-filled syringes are also available to save reconstitution.  
 
Aripiprazole long-acting injection may be injected into either the gluteal or the deltoid muscle 
from where the active moiety is slowly released into the circulation. Maximum plasma 
concentration is achieved at a median Tmax of 7 days after gluteal muscle injection and 4 days 
after deltoid muscle injection. Doses must not be divided; the suspension should be injected 
slowly as a single injection. The elimination half-life (t ½) is 29.9 days for a 300 mg dose and 
46.5 days for a 400 mg dose when administered monthly as recommended. Steady state is 
attained by the fourth injection. It should be stored at room temperature. Tolerability to oral 
aripiprazole should be established prior to initiating the injection in any patient naïve to 
aripiprazole.  
 
The recommended starting and maintenance dose is 400 mg. Initial dose titration is not 
required. It should be administered once-monthly as a single injection (no sooner than 26 
days after the previous injection). After the first injection, treatment with 10 mg to 20 mg oral 
aripiprazole should be continued for 14 consecutive days to maintain therapeutic plasma 
aripiprazole concentrations during initiation of therapy. If there are adverse reactions with the 
400 mg dosage, a reduction to 300 mg once-monthly should be considered. 
 
5.2 Olanzapine long-acting injection15 consists of olanzapine pamoate monohydrate powder 
together with a solvent which when combined form a prolonged release suspension for deep 
intramuscular gluteal injection. Vials containing olanzapine pamoate monohydrate equivalent 
to 210 mg. 210 mg, 300 mg and 405 mg of olanzapine are available which, when reconstituted 
as directed, contain 150 mg olanzapine per ml. Whilst a test dose is not required, patients 
should have been successfully treated with oral olanzapine before receiving the long-acting 
injection in order to establish tolerability and response. The release characteristics of 
olanzapine long-acting injection are not dissimilar to those of the first generation oil-based 
depots. There is an early initial release of active antipsychotic after administration. This is in 
contrast to risperidone long-acting injection (see Section 5.4). 
 
After each injection, patients must be observed for post-injection syndrome (signs and 
symptoms consistent with olanzapine overdose) in a healthcare facility by appropriately 
qualified personnel for at least 3 hours (see the SmPC for full details).  
 
5.3 Paliperidone palmitate 1 monthly16 is the palmitate ester of paliperidone formulated as 
nanoparticles suspended in an aqueous solution. These nanoparticles dissolve very slowly 
from the injection site before being hydrolysed to paliperidone and absorbed into the systemic 
circulation. This extended period of time for release allows for monthly dosing. Release of the 
active substance starts as early as day 1, gradually rises to reach maximum plasma 
concentrations at a median Tmax of 13 days and lasts for at least 4 months. 
 
Paliperidone palmitate 1 monthly is licensed for the maintenance treatment of schizophrenia in 
adult patients stabilised with oral paliperidone or risperidone. It may also be used in patients 
who are not currently on risperidone or paliperidone but who have responded to them in the 
past (as long as they are not acutely agitated and only have mild to moderate psychotic 
symptoms). This latter part of the licence allows the use of paliperidone palmitate in selected 
patients in the acute setting. A test dose is not required but response and tolerability to either 
oral risperidone or paliperidone must have been established prior to commencing treatment. 
      





Paliperidone palmitate 1 monthly is available in four dose strengths, 50 mg/ml, 75 mg/ml, 100 
mg/ml and 150 mg/ml, all presented in pre-filled syringes. To attain therapeutic plasma levels 
as rapidly as possible, the first two doses (150 mg and 100 mg) must be administered into the 
deltoid muscle 7 days apart (± 4 days). Following this initial titration period, monthly dosing 
should commence using either the deltoid or dorsogluteal site. There are special requirements 
regarding needle selection from the pack for deltoid injection in patients who weigh ≥90 
kg.(See Section 14.9 )  
 
Paliperidone palmitate is now available as a 3-monthly injection.17 It is indicated for the 
maintenance treatment of schizophrenia in adult patients who have been clinically stable on  
1-monthly paliperidone palmitate long-acting injection, preferably for 4 months or more and who 
do not require dose adjustment. This allows selected patients to maintain an optimal plasma 
level of antipsychotic with fewer administrations. It is available in pre-filled syringes containing 
175 mg, 263 mg, 350 mg or 525 mg prolonged-release suspension of paliperidone for injection.                               
 
This 3-monthly injection should be initiated in place of the next scheduled dose of 1-monthly 
paliperidone palmitate long-acting injection. The dose should be based on the previous  
1-monthly paliperidone dose using a 3.5 fold higher dose. A dosing table is available in the 
SmPC.17 
 
Following initiation it should be administered by intramuscular injection once every 3 months (± 
2 weeks). If needed, dose adjustment can be made every 3 months in increments within the 
range of 175 mg to 525 mg based on individual patient tolerability and/or efficacy. Due to the 
long-acting nature of this formulation, the patient’s response to an adjusted dose may not be 
apparent for several months. If the patient remains symptomatic, they should be managed 
according to clinical practice.   
 
 
5.4 Risperidone long-acting injection (RLAI)18 consists of risperidone encapsulated in 
microspheres of a biodegradable polymer which, after reconstitution are suspended in an 
aqueous vehicle. Vials are available containing 25 mg, 37.5 mg and 50 mg risperidone. It is 
licensed for the maintenance treatment of schizophrenia in patients currently stabilised with oral 
antipsychotics.  
      
A test dose is not required. Instead, response and tolerability should normally be confirmed by a 
previous course of oral risperidone. In those patients who have already demonstrated a response 
to risperidone, the effective oral dose is used as a guide to the initial intramuscular dose. 
 
Note: Therapeutic plasma levels of risperidone will not normally be achieved until 3-4 weeks 
after the first injection.19 This means that it will not begin to exert a significant clinical effect before 
the third injection has been given. Patients should, if possible, continue to take oral risperidone 
(or in exceptional cases their previous oral antipsychotic) for at least 3 weeks after receiving the 
first dose of risperidone long-acting injection. This also means that at least 3 injections of a 
particular dose must be given before increasing that dose. This contrasts with traditional depots 
where peak plasma levels are achieved between 3 and 5 days following the first administration. 
 
5.5 Refer to the most up-to-date information by consulting the latest published SmPC at 






6.1 Premature discontinuation of oral antipsychotics is common in patients with 
schizophrenia and is a frequent cause of relapse.20,21 Long-acting oil-based depot 
intramuscular antipsychotic injections were originally developed to improve and support 
treatment adherence and reduce the relapse rate in this population.22,23  
 
6.2 Advantages of depot and other long-acting antipsychotic injections from a healthcare 
professional’s perspective include: 
• Reduced necessity for tablets or capsules to be taken on a daily basis. 
• Reduced uncertainty about the amount of medicine taken or not taken. 
• No influence of first-pass metabolism thus improved bioavailability. 
• More consistent delivery of antipsychotic with more stable plasma levels over time 
which can minimise side effects and reduce variations in symptom control. 
• A wider window of opportunity to re-engage assertively with a patient if they refuse an 
injection as plasma levels take longer to decline after the last dose than with oral 
formulations. 
• Earlier detection of non-adherence which can be followed up quickly, resulting in 
potentially reduced relapse rates, leading to better outcomes. 
• Possibly reduced risk of admission with potential resultant cost savings. 
• Potentially reduced need for repeat prescriptions since the dosing interval of such 
formulations are normally between 1 and 4 weeks. This may also lead to cost savings. 
• Reduced risk of accidental or deliberate self-harm through overdose. 
• The potential to enhance the therapeutic relationship and partnership working with the 
patient and their carer (if appropriate) by the regular frequent contact required. 
 
6.3 Disadvantages of depot and other long-acting antipsychotic injections from a healthcare            
professional’s perspective include: 
• Pain, erythema, swelling at the site of injection as well as nodule formation, particularly 
with oil-based injections. 
• Risk of damage to nerves, arteries or veins. 
• If side effects occur, they will be prolonged until the plasma level falls. 
• There may be an allergy to an oily vehicle; hence the necessity for a test dose of the 
oil- based depot formulations.   
• The need to confirm efficacy of, and tolerability to, the oral formulations of the non-oil-
based long-acting injections where required and practical. 
• It can take several weeks for plasma levels to reach steady state. 
• Injection technique competence, assessment and training are required. 
• Potential logistical difficulties which may arise from the need to administer an injection 
to a patient who is in employment. 
• The requirement to attend a traditional ‘depot clinic’ may be considered stigmatising 
by some but research has highlighted the opposite may be true, with patients valuing 
contact with other patients and staff as well as the medication management 
interventions available to them there.24,25 
• Some people have a dislike or even a phobia of needles. 
• Social embarrassment and the need for chaperoning and gender matching. 
• Staffing and medicine storage issues. 
• The fact that depot injections have been viewed by some as stigmatising and coercive. 
 
6.4 Healthcare professionals’ perceptions of the advantages and disadvantages of these 
formulations may differ from those of patients. When considering the choice of treatment, 
patient opinion should be sought and taken into account.24,25 
 
 
6. Advantages and Disadvantages of Depot and other Long-





6.5 Advantages of depot and other long-acting injections from a patient perspective: 
• You don't have to remember to take your medicines every day. 
• You don't have to worry about family or others reminding you to take your medicine. 
• You don't have to worry about accidentally forgetting to take your medicine. 
• Injections may be a better way of ensuring that you get the medicine you need to keep 
you well than tablets or capsules. 
• Tablets and capsules can serve as a daily reminder that ‘You are ill’.  
• Injections can be given every 1 to 6 weeks and allow you more freedom to get on with 
your life and put your illness behind you. 
• Injection clinics can be a source of social interaction for some people – and there may 
also be educational material available there. 
• If you forget to go for your injection, someone will remind you. 
• You may have fewer side effects with an injection (because the levels in the blood don't 
go up and down so much). 
• You don't have to remember to take your medicines with you if you go away for a short 
holiday. 
 
6.6 Disadvantages of depot and other long-acting injections from a patient perspective: 
• Some people don't like needles.   
• You have to expose your buttocks, thigh, or shoulder – this may be embarrassing. 
• You may have to wait around until the nurse finds a chaperone. 
• The injection might be painful and the injection site may be sore afterwards. 
• Some people develop nodules or boils at the site of the injection. 
• Some people can get nerve damage if the injection is given badly or at the wrong site.        
• If side effects occur they may persist for several weeks after the injection is stopped. 
• Some feel that an injection stigmatises them or that they are being forced to have treatment 
against their will. 
 
6.7 Preventing relapse is essential not only because a relapse in schizophrenia is costly but 
also because relapse duration and treatment intensity have been associated with tissue loss 
in some brain regions together with changes in ventricular volume.26 
 
High-quality evidence to support a positive effect of long-acting injectable antipsychotics on 
adherence and the prevention of relapse has been sparse. Only a small benefit over oral 
therapy has been demonstrated in randomised controlled trials.27 One of the problems may 
be that clinical trial design investigating this area is inappropriate and creates a bias against 
the long-acting injectable formulation.28 In a systematic review and meta-analysis of long-
term studies however, long-acting injectable antipsychotics reduced relapse rates for 
outpatients with schizophrenia from an average of 33.2% to 21.5%. This represents a 10% 
absolute and a 30% relative risk reduction for relapse.29   
 
A nationwide cohort study from Finland also concluded that the use of long acting formulations 
was associated with a significantly lower risk of re-hospitalisation than oral formulations of the 
same antipsychotic.30 A meta-analysis of mirror image studies subsequently confirmed that 
long-acting antipsychotic injections reduce both the risk of hospital admission as well as the 
number of admissions compared to oral antipsychotics.31 Such studies where patients act as 
their own controls compare periods of oral antipsychotic treatment with treatment with long-
acting injectable formulations of the same antipsychotic in the same patient for similar periods.  
They are considered a better paradigm than randomised-controlled trials for such 










7.1 Patient safety is always the highest priority. 
  
7.2 There is a body of evidence that demonstrates the contribution of human factors as well as 
system failures to patient harm.32 This guidance is designed to minimise the risk of human error 
through the encouragement of systematic, safe practice. 
 
7.3 When an injection is to be given it is best practice to have a second registered practitioner 
available to double check at every stage of the procedure.6 However, this is not always possible 
in a community setting. In such circumstances, it would be deemed good practice for the patient 
or carer if appropriate to act as second checker with a record of this in the clinical notes. 
 
7.4 If at any time a registered practitioner has any concerns during a double check, the 
procedure must be stopped and a review must take place in discussion with the second-check 
registered practitioner.5,6 
 
7.5 All untoward events, including where a patient experiences an adverse event associated 
with a specific product, must be reported and recorded in accordance with the local risk-
management and untoward-incident-reporting procedures. Local policy will determine how all 
such untoward events are reported including through the UK Medicines and Healthcare 
products Regulatory Agency (MHRA) Yellow Card Scheme.33  
 
7.6 A registered practitioner who is undertaking the administration of a depot or other  
long-acting intramuscular antipsychotic injection must have:4,5 
• knowledge and understanding of the legislation, regulation and guidance applicable to the 
procedure 
• knowledge of the therapeutic use, normal dosage, side effects, precautions and 
contraindications of the injection being administered 
• competence in the technical performance of the procedure to ensure nothing is overlooked 
during the preparation, administration and following the procedure 
• an individual responsibility to keep knowledge and skills up to date and only work within 
the limits of their competence 
• the ability to apply a human factor risk reduction methodology to their practice to minimise 
any harm to the patient before, during and after the procedure 
• compassion and respect for the patient and they must pay attention to their dignity 
 
7.7 During transit of certain injections, material may accumulate in the top or bottom of an 
ampoule. This can be dislodged by gently tapping it before opening or by holding the top of the 
ampoule and swinging the arm in a large arc. 
 
Caution must be exercised when opening glass ampoules.  
 
There are two main types of ampoule (see diagrams on the opposite page): 
 
• Spot ampoules – always break away from the spot. 


















































Ring cut ampoules are more likely to shatter than spot ampoules.  
 
Historically, spot ampoule technology preceded ring-cut ampoule technology, but 









8.1 Registered practitioners have a responsibility to consider the potential stigma associated 
with the diagnosis and treatment of a mental illness. They should provide information to 
support the patient and their carers and encourage them, together with the general public, to 
engender a positive, balanced attitude. The environment in which it is planned to administer 
the medicine and exchange information can influence the perception of a good patient 
experience.34,35 
 
8.2 An oil-based depot or other long-acting antipsychotic injection should be offered to anyone 
who expresses a preference for such a formulation even after an acute episode or when the 
need to avoid covert non-adherence (either intentional or unintentional) is a clinical priority.7,8 
 
8.3 The choice and formulation of antipsychotic should be a joint decision between the patient 
and their clinician taking into consideration the risks and benefits of the treatment including the 
relative potential of individual antipsychotics to cause side effects such as extrapyramidal side 
effects (EPS) and metabolic side effects, including weight gain.7,8 
 
8.4 When starting an oil-based depot or other long-acting intramuscular antipsychotic injection 
the preferences and attitude of the patient towards regular intramuscular injections and the 
intended environment for such administration, for example in the home or the location of clinics, 
must be considered and recorded.7 
 
8.5 Where, according to the product licence, a choice of injection site exists, the patient should, 
if possible, be offered that choice. The risks and benefits of each potential administration site 
should be discussed compassionately with the patient with particular reference to dignity issues 
and the environment in which the administration will take place. The practitioner may like to 
discuss some or all of the following with the patient: 
• They may not have to take off as much clothing which may be less embarrassing, more 
respectful and less anxiety-provoking especially if they have sexual delusions or where 
cultural and/or religious issues must be considered 
• They may not have to worry so much about what to wear to have the injection 
• They may find it easier to talk to the doctor or nurse if they don't have to expose themselves 
• Where a choice of injection site exists, offering that choice may improve trust and thus the 
therapeutic relationship 
• A choice of site allows for more extensive rotation, therefore more time for recovery of the 
site between injections and fewer long-term injection site complications 
• Some injection sites may be perceived as less stigmatising than others 
• There may be more potential for face-to-face contact with their nurse and the whole 
process may be less impersonal 
• Such choice may help to improve adherence 
• Many injections are given via sites other than the dorsogluteal site and by making the 
process more akin to a general medical process, the stigma associated with antipsychotic 
injections may be reduced 
 
8.6 The availability of three long-acting intramuscular antipsychotic injections licensed to be 
given at the deltoid site (risperidone, paliperidone and aripiprazole) requires both confidence 
and competence on the part of the registered practitioner to describe this choice to the patient 
and if it is their first administration, confidence on the part of the patient in accepting treatment 
in this manner. 
  








9.1 Choice is about the power to make decisions; it gives people more control over their lives. 
Decisions can be made entirely by another person or a team which can be appropriate if no 
decision places the individual or others at risk, or if the patient requests others to make the 
decision for them. Sometimes people prefer decisions to be made by those they perceive to 
be more knowledgeable than they are.  
9.2 In contrast, a shared decision is where the healthcare professional (and/or team) and the 
individual patient pool their knowledge and understanding of what is needed to allow them to 
come to a joint decision. In this situation the decision follows an exchange of information 
where all viewpoints are expressed, listened to and respected, questions are answered and 
additional information sought and provided where required.  
9.3 The patient must be able to consider and weigh up the information provided in order to 
arrive at a decision as to whether or not to proceed with an oil-based depot or another long-
acting antipsychotic injection and they must be able to retain the key points of any discussion 
with the registered practitioner and communicate this decision back to them. 
 
9.4 There are many factors that the patient will wish to consider and all of these should be 
thoroughly explored in a person centred manner with the clinical team together with the legal 
responsibilities that registered practitioners have in England and Wales in accordance with the 
Mental Health Act 200736 and Mental Capacity Act 2005,37 and in Scotland in accordance with  
the Mental Health (Care and Treatment) (Scotland) Act 2003,38 as well as the Adults with 
Incapacity (Scotland) Act 200039 and in Northern Ireland in line with any relevant legislative and 
good practice guidance. 
 
9.5 Patient choice may be facilitated by accessing the Choice and Medication website via your 
organisation’s subscription at: https://www.choiceandmedication.org. As well as a series of 
frequently asked questions about mental illnesses and their treatment, there are ‘handy charts’ 
to enable the comparison of treatments, including oil-based depots and other long-acting 
intramuscular antipsychotic injections. This site is designed for use by patients, carers and 
professionals alike. 
 
9.6 This process of coming to a shared decision is also called concordance, in contrast to 
adherence which is medicine-taking behaviour.40 Pragmatic models and frameworks to 
support the shared decision making process include the Elicit-Provide-Elicit model41 and the 
recommendations made by NICE for patient decision aids used in consultations involving 


















10.1. Not infrequently it is deemed appropriate to change or switch an antipsychotic in order 
to achieve a better outcome for an individual patient. This may be due to lack of efficacy, 
intolerable side effects, poor adherence, physical health issues or patient choice.  
10.2 Such a switch may be between oral antipsychotics, long-acting injectable antipsychotics, 
or from an oral to a long-acting injectable antipsychotic formulation or vice versa. 
10.3 Key objectives when switching antipsychotics include the need to minimise risk to mental 
stability as well as any possible adverse effects. All potential problems should be anticipated 
and detailed in a comprehensive management plan. Most importantly, the switch must be 
completed to avoid unnecessary polypharmacy/polyprescribing. 
10.4 The pharmacokinetic and pharmacodynamic profiles of both antipsychotics involved 
must inform the switching strategy. This will enable successful titration and dosing by allowing 
the prediction and thus avoidance of possible problems such as adverse effects or withdrawal 
symptoms. 
10.5 Differences in elimination half-lives (t1/2) and peak plasma concentrations (Cmax) lead to 
different plasma profiles. The elimination half-life of an antipsychotic normally determines its 
dosing regimen. It is the time taken for the plasma concentration to fall by half its original 
value. For oral formulations it takes approximately five half-lives to reach steady state. It takes 
the same time for an oral antipsychotic to disappear from the plasma when it is discontinued 
at steady state.   
10.6 Such information together with knowledge of the respective receptor affinities allows the 
prediction of therapeutic effects plus withdrawal and rebound effects which can occur during 
discontinuation and switching especially if the new antipsychotic does not share the same 
receptor profile and affinity with the first. 
10.7 A specific switching strategy based on such knowledge can enhance effectiveness and 
avoid undesirable effects. There are at least eight different possible strategies for switching 
oral antipsychotics.42 
10.8 Due to the various techniques employed to produce a long-acting injectable formulation, 
the time to steady state cannot be calculated as five half-lives with long-acting antipsychotic 
injections in the same way as with oral formulations. Details of their pharmacokinetic 
parameters together with specific switching strategies taken from each individual SmPC11 and 
the Maudsley Prescribing Guidelines19 may be found on the following pages. 
       10.9 Whenever possible a specialist mental health pharmacist should be enlisted to assist in    
drawing up a management plan with an appropriate switching strategy.















Approximate Pharmacokinetic Data for Oil-based Depot and 
Other Long-acting Antipsychotic Injections11,19 




Time to peak 










Flupentixol decanoate (Depixol) 1 week 7 days 8-17 days 2 months 2-4 weeks 
Fluphenazine decanoate (Modecate)* 1 week 8-12 days 10 days 2 months 2 weeks 
Haloperidol decanoate  (Haldol) 4 weeks 3-9 days 21 days 2-4 months 4 weeks 
Pipotiazine palmitate  (Piportil)* 1 week 7-14 days 15 days 2 months 4 weeks 
Zuclopentixol decanaote  (Clopixol) 3 weeks 4-7 days 19 days 3 months 1-4 weeks 
Other Long-acting Antipsychotic Injections 




7 days (gluteal inj.) 
4 days (deltoid inj.) 
30 days - 300mg dose 





Olanzapine pamoate (ZypAdhera) N/A 2-3 days 30 days 3 months 2-4 weeks 
dep. on dose 
Paliperidone palmitate - 1 monthly 
(Xeplion) (PP1M) 
N/A 13 days 
(an average 28% 
higher Cmax was 
observed with deltoid 
compared with gluteal 
injection.) 








Paliperidone palmitate  -3 monthly 
(Trevicta) (PP3M) 
 
N/A 30-33 days 
(11-12% higher with 
deltoid compared with 
gluteal injection.) 
84-95 days following 
deltoid injection  and  
118-139 days following 
gluteal injection. 
N/A as pt. will  already 
be at SS on initiation 
having been on PP1M 
For 4 months 
12 weeks 
Risperidone (Risperdal Consta) 2 weeks 4–5 weeks 4 days 2 months 2 weeks 
* Modecate and Piportil have been discontinued in the UK by the manufacturers. 







Switching TO an oil-based depot  
From an oral antipsychotic • Continue the oral antipsychotic for 1 – 4 weeks from the first oil-based depot 
injection – depending on the “time to steady state” of the oil-based depot 
From another oil-based depot 
 
• Give the new oil-based depot instead of the next due injection of the first oil-
based depot. 
• Do not give any more doses of the first oil-based depot 
From another long acting antipsychotic injection (LAI) but not 
risperidone LAI 
• Give the oil-based depot instead of the next due injection of the LAI 
• Do not give any more doses of the LAI 
From risperidone LAI 
 
• Give the oil-based depot 2–4 weeks after the last injection of risperidone LAI 
was due. i.e. 4-6 weeks after the last injection of risperidone LAI was given. 
(The last injection of risperidone LAI  provides therapeutic plasma levels  for 4 -
6 weeks with a post dose peak at 5 weeks) 
• Do not give any more risperidone LAI 
Switching TO Aripiprazole LAI  
From oral antipsychotics 
 
• Plateau cross taper the oral antipsychotic to oral aripiprazole over 2 weeks  
• Start the aripiprazole LAI 
• Continue oral aripiprazole for two more weeks then stop 
From oil-based depot or another LAI antipsychotic except 
risperidone LAI 
• Start oral aripiprazole on the day the last depot or LAI  antipsychotic dose was 
due 
• Start the aripiprazole LAI after two weeks 
• Stop the oral aripiprazole two weeks later 
From risperidone LAI 
 
• Start oral aripiprazole 2-4 weeks after the last injection of risperidone LAI was 
due. I.e.4-6 weeks after the last injection of risperidone LAI was given. Do not 
give any more risperidone LAI (The last injection of risperidone LAI  provides 
therapeutic plasma  levels  for 4 -6 weeks with a post dose peak at 5 weeks) 
• Start the LAI aripiprazole two weeks later 






Switching Strategies11,19 (continued) 
 
 
Switching TO Olanzapine LAI  
Following a successful trial of oral olanzapine • A direct switch to olanzapine LAI is possible 
From another oral antipsychotic • A direct switch is possible but prior oral antipsychotics are probably best reduced 
slowly after starting olanzapine oral or LAI 
From an oil-based depot or another LAI antipsychotic except  
risperidone LAI 
 
• Oral olanzapine or olanzapine LAI can be started on the day the previous oil-based 
depot or LAI was due.  
• Do not give another dose of the first oil-based depot or LAI 
From risperidone LAI 
 
• Begin the olanzapine LAI 2-4 weeks after the last injection of risperidone LAI was 
due. i.e. 4-6 weeks after the last injection of risperidone LAI was given. (The last 
injection of risperidone LAI provides therapeutic plasma levels for 4 -6 weeks with 
a post dose peak at 5 weeks) 
• Do not give any more risperidone LAI 
Switching TO Paliperidone LAI One monthly (PP1M)  
From oral paliperidone or oral risperidone 
 
• Give the two initiation doses of 150 mg on treatment day 1 and 100 mg one week 
later on day 8, both into the deltoid muscle as per the SmPC16 
• The third dose should be administered one month after the second initiation dose  
• No oral supplementation is necessary during initiation of paliperidone LAI (PP1M) 
From other oral antipsychotics 
 
• Give the two initiation doses followed by the maintenance dose as above 
• Reduce the oral antipsychotic over 1-2 weeks following the first injection of PP1M  
From an oil-based depot or another LAI antipsychotic except 
risperidone LAI 
 
• Start the  PP1M at the maintenance dose when the next injection of an oil-based 
depot or other LAI antipsychotic was due instead of the oil-based depot or  LAI 
• No initiation doses are required 
• Do not give another dose of the oil-based depot or LAI 
From risperidone LAI 
 
• No initiation doses of PP1M are necessary 
• Begin an equivalent dose of PP1M 2-4 weeks after the last injection of risperidone 
LAI was due. i.e. 4-6 weeks after the last injection of risperidone LAI was given. 
(The last injection of risperidone LAI  provides therapeutic levels for 4-6 weeks 
with a post dose peak at 5 weeks) 






Switching Strategies11,19  (continued) 
Switching TO Paliperidone LAI three monthly 
(PP3M)* 
 
From paliperidone LAI one monthly (PP1M) (only those stable 
on PP1M, preferably for the past 4 months or more, and not 
requiring a dose increase may be switched to PP3M)  
• Patients must have been be adequately treated with PP1M (preferably for four 
months or more), be stable and not require any dose adjustment  
• PP3M should be initiated in place of the next scheduled dose of PP1M (± 7 days).  
• The PP3M dose should be based on the previous PP1M dose using a 3.5 fold higher 
dose  
• A dose conversion chart is available in the SmPC of PP3M17 
• If needed, dose adjustments can be made every 3 months in increments within the 
range of 175 mg eq. to 525 mg eq. based on individual patient tolerability/efficacy 
• Due to the long-acting nature of PP3M, the patient’s response to an adjusted dose 
may not be apparent for several months 
• If the patient remains symptomatic, they should be managed according to clinical 
practice 
Switching TO Risperidone LAI  
From oral risperidone 
 
• Give the equivalent does of risperidone LAI and continue with the oral risperidone 
for at least 3 weeks then taper down over 1-2 weeks.  
• Be prepared to continue oral risperidone for longer if necessary 
From other oral antipsychotics 
 
• Either:. Switch to oral risperidone and titrate to an effective dose.   
• If tolerated and effective prescribe an equivalent dose of risperidone LAI and 
continue with the oral risperidone for at least 3 weeks then taper down over 1-2 
weeks.  
• Be prepared to continue oral risperidone for longer if necessary 
• Or: Give an appropriate dose of risperidone LAI and then slowly discontinue the oral 
antipsychotic after 3 -4 weeks.  
• Be prepared to continue the oral antipsychotic for longer if necessary 
From an oil-based depot or other LAI Give risperidone LAI one week before the last injection of oil-based depot or other LAI 
is given 
 
*   PP3M requires vigorous shaking with the tip up and a loose wrist for at least 15 seconds to ensure a homogeneous suspension prior to       







11.1 Assessment of capacity to consent is a critical part of preparation for the procedure and 
must be consistent with guidance from the Care Quality Commission,43 the Mental Health Act 
2007,35  the Mental Capacity Act 200536 and the recommendations in NICE Guideline NG108 
on decision making and mental capacity.44 Practitioners need to be especially familiar with 
Part 4 of the Mental Health Act 2007 relating to consent to treatment and Part 4a relating to 
the treatment of community patients not recalled to hospital.  
 
11.2 A patient must be assumed to have capacity unless it is established that they lack 
capacity.44 If there is any doubt about the capacity of the patient, then a documented 
assessment must be undertaken and the injection must not be given until this is clarified. 
 
11.3 Obtaining consent from a patient is a complex process and must take into consideration 
the patient’s ability to understand information about oil-based depot and other long-acting 
intramuscular antipsychotic injections, their routes of administration as well as the risks and 
benefits of such treatments. 
 
11.4 The process of consent must not involve coercion of the patient to agree to treatment 
and on this basis, it is essential to promote practice that is in accordance with the Mental 
Health Act 200735 and the Mental Capacity Act 2005.36 
 
11.5 For any patient detained under any of the Mental Health Act sections 4, 5(2), 5(4), 35, 
135,136, 37(4) or 45A, consent to treatment provisions, as defined in part 4, do not apply and 
they are in the same legal position as patients who are not subject to the Mental Health Act 
2007. This means that they can refuse treatment. Part 4 similarly does not apply to patients 
who are conditionally discharged under Sections 42(2), 73 and 74 of the Mental Health Act 
2007 and have not been recalled to hospital.35 
 
11.6 Consent to treatment provision under Part 4 applies to patients who are detained under 
Section 2, 3, 36, 37 (except 37(4)), 38, 44, 45A, 47, and 48. Patients who are on a Supervised 
Community Treatment Order (CTO) cannot be compelled to accept treatment they absolutely 
refuse unless they are recalled to hospital and their section 3 reinstated. This means that the 
registered practitioner has to make sure that they are legally entitled to administer medication 
and that the appropriate Mental Health Act documentation is completed accurately and, in the 
case of medication received for at least 3 months, form T3 is available with the prescription/ 
administration card.35 
 
11.7 Section 62 of the Mental Health Act 200735 allows for the emergency treatment of a 
detained patient whatever section they are on, providing it is necessary to save life or prevent 
serious harm. The treatment should be non-hazardous and not have irreversible effects.35 
Rapid tranquillisation with the use of short-acting intramuscular antipsychotics may feature 
here but the initiation of oil-based depot or other long-acting intramuscular antipsychotics 



















11.1/S Assessment of capacity to consent is a critical part of preparation for the procedure 
and must be consistent with the Mental Health (Care and Treatment) (Scotland) Act 200337 
and its Code of Practice,45 Consent to Treatment Guidelines of the Mental Welfare 
Commission for Scotland,46  and the Adults With Incapacity (Scotland) Act 200038 along with 
its Code of Practice.47 Practitioners need to be especially familiar with Part 16 of the Mental 
Health (Care & Treatment) (Scotland) Act 200337 relating to safeguards on medical 
treatments. 
 
11.2/S The law of Scotland generally presumes that adults are capable of making decisions 
for themselves. That presumption can be overturned in relation to particular matters or 
decisions on evidence of impaired capacity. If in doubt, a documented assessment must take 
place first. 
 
11.3/S Obtaining consent from a patient is a complex process and must take into 
consideration the patient’s ability to understand information about oil-based depot and other 
long-acting intramuscular antipsychotic injections, their routes of administration, as well as 
the risks and benefits of such treatment. 
 
11.4/S The process of consent must not involve coercion of the patient to agree to treatment 
and on this basis it is essential to promote practice that is in accordance with the Mental 
Health (Care and Treatment) (Scotland) Act 200337 and the Adults With Incapacity (Scotland) 
Act 2000.38 
 
11.5/S Under Part 16 of the Mental Health (Care and Treatment) (Scotland) Act 2003,37 
treatment can be given for the first 2 months from the first date of treatment as part of a 
Compulsory Treatment Order or an Interim Compulsory Treatment Order. After 2 months 
specific safeguards are activated. Under Section 238 of Part 16 of the 2003 Act, where a 
patient is capable of consenting and consents, then the patient’s Responsible Medical Officer 
is required to certify that the necessary conditions are met using a T2 form. Under Section 
241 of Part 16 of the Mental Health (Care and Treatment) (Scotland) Act 2003,37  where the 
patient is incapable of consenting or does not consent, then a Designated Medical Practitioner 
can authorise treatment using a T3 form only if the necessary conditions are met. 
 
11.6/S Under Section 112 of the Mental Health (Care & Treatment) (Scotland) Act 2003,37 a 
patient on a Compulsory Treatment Order or an Interim Compulsory Treatment Order which 
imposes an attendance requirement with a view to receiving treatment who fails to comply 
with the attendance requirement can be compelled to attend any hospital or the required place 
of attendance and detained there for no more than 6 hours.37 However, treatment cannot be 
forced outside of a hospital setting. Under Section 113 of the Mental Health (Care and 
Treatment) (Scotland) Act 200337 if a patient is subject to a Compulsory Treatment Order or 
an Interim Compulsory Treatment Order which does not authorise detention in hospital and 
the patient fails to comply with any measure specified in the treatment order and it is a matter 
of urgency then the patient may be taken into hospital for a period of up to 72 hours. 
 
11.7/S In Scotland a patient cannot be treated under Part 16 of the Mental Health (Care & 
Treatment) (Scotland) Act 200337 under a Section 36 Emergency Detention Certificate without 
their consent unless the need for treatment is urgent, as per Section 243 of the Mental Health 
(Care & Treatment) (Scotland) Act 2003.37  Rapid tranquillisation with the use of a short-acting 
intramuscular antipsychotic may feature here but the initiation of an oil-based depot or other 
long-acting intramuscular antipsychotic could not be justified.





11.1/NI Assessment of capacity to consent is a critical part of preparation for the procedure 
and must be consistent with practice guidelines from the General Medical Council,48  the Royal 
Pharmaceutical Society (RPS) and Royal College of Nursing (RCN),5 the Northern Ireland 
Social Care Council49 and the Regulation and Quality Improvement Authority.50 
 
11.2/NI The registered practitioner caring for the patient may presume the patient has the 
capacity to consent to treatment; however if there is any doubt about the capacity of the patient, 
then a documented assessment must be undertaken and the treatment not given until this is 
clarified. 
 
11.3/NI Obtaining consent from a patient is a complex process and must take into consideration 
the patient’s ability to understand information about oil-based depot and other long-acting 
intramuscular antipsychotic injections, their routes of administration as well as the risks and 
benefits of such treatments. 
 
11.4/NI The process of consent must not involve coercion of the patient to agree to treatment 
and on this basis it is essential to promote practice that is in accordance with the Mental Health 
(Northern Ireland) Order 198651 and good professional practice guidelines. 
 
11.5/NI Patients admitted for assessment under the Mental Health (Northern Ireland) Order 
198651 can still refuse treatment during the assessment period (i.e. if they are on forms 5, 7, 8 
or 9) but not once they are detained for treatment. Once detained, a course of medicines for 
mental disorder can be given for up to 3 months without consent or need for an independent 
medical opinion. The patient must be made aware of their right to appeal detention under the 
Mental Health Order. 
 
11.6/NI After 3 months have elapsed from the start of medical treatment then either forms 22 
or 23 need to be completed for treatment to proceed. This requires that a doctor (as stipulated 
in Part IV of the Order) certifies that either the patient is capable of giving valid consent and 
does so or that the patient either lacks capacity to consent or has not given consent but the 
treatment should proceed for the therapeutic needs of the patient. 
 
11.7/NI Article 68 of the Mental Health (NI) Order 198651 allows for the urgent treatment of a 
detained patient providing it is necessary to save life or prevent a serious deterioration in the 
condition of the patient or serious suffering by the patient. Rapid tranquillisation with the use of 
a short-acting intramuscular antipsychotic or benzodiazepine may feature here but the initiation 
of long-acting intramuscular antipsychotic formulations is unlikely to be justified under this 
provision. 
 
11.8/NI As yet Northern Ireland has no equivalent to England’s Mental Capacity Act 200536 or 
Scotland’s Adults with Incapacity Act 2000.38 Therefore, where there is doubt over the capacity 
of the patient to give consent, reference must be made to good professional practice guidelines 
and to common law. Patients are assumed to have capacity unless or until it is shown 
otherwise. If there is doubt, then it must be examined in more detail. To demonstrate capacity 
for a particular decision a patient must be able: 
 
• To understand and retain information given to them (about the medicines, in this 
case) 
• To consider the information, show understanding of the consequences of their choice 
and communicate their decision 
 
11.9/NI All patients can withdraw consent at any time. If this occurs, a review of the patient’s 
mental state, his or her capacity to give valid consent and a discussion with the multidisciplinary 
team is appropriate




12.1 There are some key principles in the preparation of the patient which are crucial to 
gaining patient and carer confidence. These include the demonstration of compassion, a 
personalised approach and a desire to work in partnership with the patient and their carer(s) 
where appropriate. 
 
12.2 The administration of any medicine is an opportunity for assessment and information 
exchange with the patient and their carers (where appropriate). Preparation should include an 
assessment to see if the physical and/or mental health of the patient has changed since the 
previous contact. Any beneficial effects or side effects experienced since the last injection 
should be considered and questions asked of the patient and their carer (if appropriate) to elicit 
any concerns or information needs. 
 
12.3 Preparation at the point of administration will include the registered practitioner exercising 
accountability for checking the following: checking the prescription to confirm that the dose is 
due and that it hasn’t already been given; that the intended route, dose and formulation all 
correlate accurately with the prescription; that there are no contraindications; that any dose 
calculation is accurate; that the patient’s capacity to consent is confirmed and that the 
preparation of the injection for administration is correct and that it is in date.5,6 It is good practice 
for a second-registered practitioner to double check these too.6 In the absence of a second 
professional it is good practice to get the patient or carer to check the expiry date of the injection 
and that the dose is correct according to the prescription, etc. and record this in the notes. 
 
12.4 Finally the registered practitioner must confirm both verbally and via the available 
documentation that the patient does not have any allergy/sensitivity or religious/cultural beliefs 
which preclude the administration of the injection. This includes allergy/sensitivity to, or 
concerns regarding, the vehicle (e.g. sesame oil) or any excipient such as benzyl alcohol. 
 
12.5 Since the last administration of the injection, any change in capacity must be considered 
and again if there is any doubt about this, an assessment must be undertaken. 






13.1 The patient should be made aware of the imminent procedure and their capacity and 
consent should be assessed and confirmed respectively and recorded in their clinical notes. 
 
13.2 The patient should then be assisted if necessary, into the chosen position for 
administration of the injection according to the appropriate chosen site. 
See Appendix 1: Standard Operating Procedures 3-6 (SOPs 3–6). 
 
13.3 If there is variance from the recommended position, this must be recorded in the clinical 
notes or record together with the rationale for this clinical decision. This is generally a more 
common issue when the procedure takes place in the patient’s home rather than in a clinical 
environment. For example, where a choice of dorsogluteal or possibly ventrogluteal injection 
is made the patient may have a preference to stand to receive their injection rather than lie 
down. However, standard procedures and principles must still be adhered to.  For example, 
the patient must be asked to take the weight off their foot on the side where the injection is to 
be administered to reduce tension and steps must be taken to ensure that the patient cannot 
fall and injure themselves or the registered practitioner. 
 
13.4 Preparation for the administration of an injection begins with hand hygiene. Effective 
hand cleansing is the single most effective action in preventing the spread of infection and 
NHS England and NHS Improvement describe a hand-cleansing technique which should be 
adhered to.52  




13.5 Skin cleansing around the injection site should be undertaken according to local trust 
policy, however, this is a widely debated topic with some evidence supporting the fact that in 
socially clean patients such skin cleansing is unnecessary.53 If the skin is cleansed with an 
alcohol swab, a period of 60 seconds (or the recommended product-related specific time) 
must elapse before the injection is administered to ensure that the alcohol has dried on the 
skin and to avoid a stinging sensation for the patient. Cotton wool balls stored wet in a multi-
use container must not be used. 
 
13.6 It is important to evaluate the injection site pre- and post-injection observing for any 
swelling, pain, inflammation, infection or tissue damage. If any of these is present it must be 
recorded in the patient’s health record and the decision to proceed reviewed. These are all 
clinical indicators that further physical assessment is urgently needed prior to any subsequent 
injection and an alternative site may need to be considered before proceeding with the 
injection. 
 
13.7 Any special instructions for post-injection monitoring in the product licence/summary of 
product characteristics (SmPC) MUST be planned for and followed. For example, after 
administration of olanzapine long-acting injection the patient must be monitored for at least 3 
hours for signs and symptoms consistent with olanzapine overdose.15 







14.1 The expiry dates of all equipment must be checked before use. Syringes and needles 
must be used systematically, safely and securely and all risk associated with their use 
minimised.1 Where an antipsychotic for injection is provided in a pack together with a syringe 
and needle for administration, the technology will have been subjected to a rigorous 
evaluation process in order for the company to gain a marketing authorisation (product 
licence) for their product. The syringe and needle provided MUST ALWAYS be used. It is 
important to read the manufacturer’s instructions regarding syringe and needle selection as 
packs and presentations may vary. Always refer to the SmPC for guidance on the use of 
needles. Where the practitioner has to select an appropriate syringe and needle it is 
necessary to consider the following: 
 
14.2 Syringes come in three main types of fittings: Luer lock, Luer slip tip and eccentric/ 
concentric Luer slip tip. The Luer lock type is generally used for intramuscular injections. The 
needle must be attached in a push-and-twist manner ensuring the chamfer of the needle is in 
the same line of sight as the graduation on the syringe. Simply sliding the needle hub onto 
the syringe will not ensure a secure fitting. 
 
14.3 The smallest possible size of syringe should be selected to accommodate the volume of 
the product to be given.54 
 
14.4 The gauge of the needle refers to the outer diameter of the needle, not the length of the 
needle nor its internal bore (lumen). Various needle lengths are available for any given gauge 
and some needles are manufactured with larger internal bores than standard to 
accommodate the particular needs of a specific product. Smaller gauge numbers indicate 
larger outer diameters.  Needles in common medical use range from 7 gauge (the largest) to 
33 (the smallest) on the Stubs scale. Inner diameter depends on both gauge and wall 
thickness. Thin-wall needles have identical outer diameters but larger inner diameters for a 
given gauge. 21-gauge needles (green hub) are most commonly used for intramuscular 
injections. The narrowest needle which complies with the product licence should be used. 
Where needles are supplied with an injection, ONLY those needles should be employed. 
 
14.5 Needle length is indicated on the needle pack in inches and/or millimetres. A variety of 
lengths is available and an assessment of the length of needle required to reach the muscle 
should be made by an assessment of the individual patient, taking into account any 
subcutaneous fat. Historically approximately 2–3 mm of the needle length was left outside the 
skin to allow the needle to be removed should it break. Although several nursing authors and 
textbooks continue to recommend this practice, they all tend to cite the opinion of one 
author.55 Today’s single-use hypodermic needles are subject to robust quality control on 
manufacture and as a result are unlikely to break. Therefore this ritualistic practice needs to 
be balanced against the need to maximise the length of needle available to reach the muscle.   
 
14.6 Research suggests that the thickness of subcutaneous tissue varies based on gender 
and Body Mass Index (BMI), which should be used to guide site and needle length for gluteal 
intramuscular injections.56,57 A few studies have measured this thickness and compared with 
needle length,56 although with varied results and methodological limitations.56,57 The best 
quality research in this area used ultrasound to measure subcutaneous tissue depth at both 
the dorsogluteal and ventrogluteal sites.57 The results suggest that both gluteal injection sites 
should be avoided in obese (BMI ≥30) individuals of any gender, unless a 51mm needle is 
used.57 In non-obese individuals of any gender, a 38mm needle should be used at the 
dorsogluteal site and a 32 mm needle should be used at the ventrogluteal site for men and 
normal-weight women, but a 38mm needle is required for overweight (BMI ≥25) women.57 
There are various reports and studies in the literature which propose a correlation between 
injection into fat and the development of granulomas.58 However, it is important to note that 
the impact of injecting long-acting antipsychotics into fat has not yet been studied so potential 
effects on effectiveness or subsequent adverse events are unknown. 
 





14.7 Only the needles recommended and supplied by the manufacturer may be used for the 
injection of aripiprazole long-acting injection. For gluteal administration the recommended 
needle is a 38 mm (1.5 inch), 22-gauge hypodermic safety needle; for obese patients with a BMI 
>28 kg/m2, a 50 mm (2 inch), 21-gauge hypodermic safety needle should be used. For deltoid 
administration the recommended needle is a 25 mm (1 inch), 23-gauge hypodermic safety 
needle; for obese patients, a 38 mm (1.5 inch), 22-gauge hypodermic safety needle should be 
used.14   
 
14.8 Only the Needle-Pro® safety needles supplied in the pack may be used for administering 
olanzapine long-acting injection. For obese patients, the 50 mm needle is recommended. If the 
50 mm needle is to be used for the injection, then the 38 mm safety needle should be used to 
withdraw the required volume of suspension. If the 38 mm needle is to be used for the injection, 
then the 50 mm safety needle should be used to withdraw the required volume slowly. Some 
excess suspension will remain in the vial. This is normal ‘overage’. The needle safety device 
should be engaged and the needle removed from the syringe. The remaining safety needle 
should then be attached to the syringe prior to injection.15 
 
14.9 Similarly for paliperidone palmitate, only the needles supplied in the dose pack should be 
used. The 22G 1½-inch safety needle (0.72 mm x 38.1 mm) (grey hub) needle should be used 
for dorsogluteal and deltoid injections in patients over 90 kg. The 23G 1-inch safety needle (0.64 
mm x 25.4 mm (blue hub) needle should be used only for deltoid injections in patients under 90 
kg. After injection, the Needle-Pro® device should be engaged and both the used needle and 
unused needle discarded appropriately.16 
 
14.10 Only the Needle-Pro® safety needles supplied in the pack by the manufacturer may be 
used for administering risperidone long-acting injection. The packs contain two needles15 and 
both are fitted with a Needle-Pro® safety device. The critical feature in each case is the needle 
bore. The 20g (yellow hub) needle has a thin wall and the 21g (green hub) needle has an ultra-
thin wall. (These walls are thinner than standard 20g and 21g needles.) These thin walls result 
in a larger bore or lumen than standard needles. This is essential to allow the risperidone 
suspension to flow freely through the needle. The 2 inch 20g needle (yellow hub) must be used 
for the intra-gluteal injection and the 1 inch, thinner 21g needle (green hub) must be used for 
intra-deltoid injection.17 
 
14.11 Retractable needles have a built-in safety mechanism that is activated by fully depressing 
the plunger while the needle is still in the patient. Once activated, the needle is automatically 
retracted from the patient, virtually eliminating exposure of the practitioner to the needle. 
Retractable needle systems come in all gauge sizes and are more costly but safer alternatives 
to using standard needles and syringes. 
 
14.12 Organisations implementing safer sharps procedures to meet European Union legislative 
requirements may wish to introduce a variety of needle protection mechanisms including 
retractable and safety needles (needles with a safety guard). When asked to use these the 
practitioner must make sure they have been trained in their use and that the particular device 
has been risk assessed for use with long-acting antipsychotic injections. For example the correct 
gauge and range of needle lengths required must be available for the diluent and to meet the 
needs of individual patients. Healthcare professionals have a pivotal role to play in assessing 
risk and evaluating any proposed new safety devices introduced in their clinical area.59 
 
14.13 It is common practice to change the needle used for drawing up to a different needle for 
administration. This is unnecessary unless there has been a risk of blunting the needle (e.g. by 
perforating a rubber bung or by scratching it on the inside of an ampoule). Blunt drawing-up 
needles with an internal filter are now available to prevent the accidental drawing up of 
contaminants from glass ampoules. However, the viscosity (thickness) of the oil and size of the 
molecules in some oil-based depot injections may make drawing up through a filter needle 
difficult and could result in some of the product being discarded with the draw-up needle when 







15.1 The Health and Social Care Act 2008 Code of Practice sets out clear guidance to ensure 
that patients receive safe care in a clean environment and that the risk of healthcare-acquired 
infection is kept as low as possible.60 Regulations implementing European Union [EU] law came 
into force across the UK on 11 May 201361 and apply across the NHS and independent 
healthcare sector. The ‘Sharps Directive’ – European Council Directive 2010/32/EU introduced 
new requirements for employees to report sharps injuries and employers to promote the safe 
use and disposal of sharps, provide information and training for employees, respond effectively 
if an injury occurs and review their procedures regularly.62 
 
15.2 The standard safety procedures adopted in the United Kingdom  for the prevention of 
inoculation incidents to healthcare practitioners are known as ‘Standard’ or ‘Universal 
Precautions’, where all blood and body fluids regardless of source are considered to contain 
infectious agents and are treated as such. Guidelines to this effect were published by the 
Department of Health in 1998.63 
 
15.3 Hand hygiene before and after each patient contact and after contact with blood or other 
body fluids is the single most effective action that can be employed to prevent the spread of 
infection. 
 
15.4 Personal Protective Equipment should be worn as appropriate and as directed by the UK 
Government. Disposable gloves, an apron and eye protection are currently recommended 
wherever there is a risk of splashing of blood or other body fluids. 
 
15.5 Any cuts or abrasions must be covered with waterproof dressings. 
 
15.6 Immediately safely dispose of sharps into an appropriate, puncture-proof, labelled sharps 
bin that is not overfilled. 
 
15.7 Never re-sheath needles or detach the needle from the syringe barrel prior to disposal. 
 
15.8 The use of retractable needles and syringes significantly reduces the risk of exposure to 
blood-borne viruses (BBVs) but these may not be suitable for long-acting antipsychotic injections 
if the appropriate length and/or gauge of needle are not available from manufacturers.62 
 
15.9 Any needle stick (inoculation) injury must be followed immediately by the application of first 
aid to bleed and wash the puncture. Local risk management procedures for reporting the incident 
must be followed and medical support sought through occupational health services. 
 
15.10 Disposable gloves should be worn as part of standard precautions. These do not prevent 
needle stick (inoculation) injury but penetration through the wall of the glove by the needle will 
remove some of the blood before the needle next penetrates skin.  
 
15.11 The report of a 9-year study conducted by Public Health England across 159 centres on 
significant occupational exposure to blood-borne viruses amongst healthcare workers, showed 
that needle stick injuries were the most commonly reported type of significant exposure, with 
65% of such injuries caused by hollow-bore needles. 42% occurred amongst nurses and 
healthcare assistants and 41% amongst doctors. Despite not typically providing direct clinical 
care to individuals, 1.5% of the exposures occurred in ancillary staff, which highlights the need 
to provide safe working conditions for all staff working in healthcare settings.64 
 
15.12 Should any accidental spillage or splash of medicine onto the skin or into the eye occur, 
the registered practitioner must follow their local risk management and untoward incident 
reporting procedures. 






16.1 Most oil-based depot antipsychotic injections must be administered only into the gluteal 
muscle by deep intramuscular (IM) injection. The exceptions to this are flupentixol and 
zuclopenthixol depots which are also licensed to be administered via the lateral thigh.65,66,67,68 
 
16.2 The Summary of Product Characteristics (SmPC)11 for each antipsychotic injection 
contains full details of the sites for which each is licensed.  These are all available online from 
the electronic Medicines Compendium: http://www.medicines.org.uk/emc/ 
 
16.3 The product licence for aripiprazole long-acting injection allows administration into either 
the gluteal or the deltoid muscles.14 
 
16.4 The product licence for olanzapine long-acting injection allows administration only into 
the gluteal muscles.15 
 
16.5 The product licence for paliperidone long-acting injection states that the first two initiation 
doses on Day 1 and Day 8 must be administered into the deltoid muscle in order to attain 
therapeutic concentrations rapidly, thereafter the monthly maintenance doses may be 
administered in either the deltoid or gluteal muscles.16 
 
16.6 The product licence for risperidone long-acting injection allows administration into either 
the gluteal or the deltoid muscles.18 
 
16.7 Registered practitioners have a responsibility to explore the possible sites of 
administration with the patient and to discuss and record their preference in accordance with 
their capacity to understand information about the risks and benefits associated with each 
site. The Summary of Product Characteristics (SmPC) will identify which muscle group an 
injection is licensed for. 
 
16.8 Where alternative sites of administration are possible, a joint decision on the preferred 
site is likely to influence adherence to future treatment and enhance the patient’s perception 
of safety and dignity. 
 
16.9 Any local procedure relating to privacy and dignity must be adhered to. This may include 
arrangements for working alone as a registered practitioner as well as chaperoning 
arrangements. 
 
16.10 Whichever site is selected for administration of the injection, the registered practitioner 
must alternate between the left and right side of the body on each occasion the injection is 
administered. The site used on each occasion must be recorded in the patient’s clinical 
record. Alternating injection sites can increase the time between injections in each site and 
allows more time for each site to heal, reducing the potential for damage to the injection site. 
16. Choice of Injection Site 






17.1 Short-acting intramuscular injections provide fairly rapid uptake of the medicine into the 
circulatory system via the muscle fibres of skeletal muscle. They are normally aqueous. 
 
17.2 An oil-based depot antipsychotic injection consists of the antipsychotic esterified to a 
decanoate or palmitate which is then dissolved in an oily vehicle. The volume to be injected is 
deposited deep into the muscle, usually the gluteal and forms a depot from where it leaches 
over time into the bloodstream according to its oil: water partition coefficient. This, together with 
the time taken for circulating enzymes to hydrolyse the ester back to its active base, is 
responsible for the prolonged action of these formulations. 
 
17.3 Long-acting antipsychotic injections which are not oil-based (e.g. aripiprazole, olanzapine, 
paliperidone, risperidone) must also be administered by deep intramuscular injection. 
 
17.4 When a deep intramuscular injection is administered the needle is passed through the 
epidermis and dermis of the skin and then through the subcutaneous fat layer, depositing the 
medicine into the skeletal muscle below. 
 
17.5 Z-tracking is the recommended technique for all deep IM injections as it creates a broken 
injection pathway (the z-track) containing the medicine in the intended target muscle and 
preventing it from moving back up the track to leak out at the skin surface.69 This has the 
advantage of achieving the correct plasma concentration whilst minimising the risk of pain or 
lesions at the injection site (see Appendix 1, SOP 2). 
 
17.6 There are five main sites that can be used for deep intramuscular injection: the deltoid, the 
dorsogluteal, the ventrogluteal, the vastus lateralis, and the rectus femoris.69 The product 
licences of individual antipsychotic injections indicate which sites are permitted. Currently none 
of the depot or other long-acting antipsychotic injections is licensed for administration at the 
rectus femoris site. A greater risk of muscle and nerve damage at the rectus femoris site has 
recently been demonstrated so use of this site is not recommended.70 
 
17.7 Each site has a maximum volume of solution that the muscle fibres can comfortably and 
effectively accommodate and each has specific advantages and disadvantages. These are 
detailed in the table on the following pages. 









Injection Sites  
Normal and range 








Injections into the mid deltoid muscle produce a quick uptake of 
the medicine. The maximum which can be safely injected is 
unknown and based on opinion. Common practice is to use this 
site for small-volume injections such as vaccinations.71  
Unknown 
(range 0.5 to 2.0 ml is 
usual in practice) 
Deltoid 
Dorsogluteal 
The dorsogluteal site, colloquially called the ‘upper outer 
quadrant’, targets the gluteus maximus muscle. 
When this site is used, there is a risk that the medicine will not 
reach the target muscle, but instead will be injected into 
subcutaneous fat.56,57 As a result, delayed uptake of the medicine 
will occur and tissue irritation or the development of granulomas 
may result.58 The clinical significance of delayed uptake is currently 
unknown. 
38 mm needles should generally be used, but are unlikely to 
reach the dorsogluteal muscle in obese (BMI ≥30) patients of any 
gender. If a patient is obese, a 51mm needle or alternative 
injection site should be used.57  
Additionally, the system of visually bisecting the buttocks to 
landmark the site is flawed and can result in damage to the 
sciatic nerve or gluteal artery, both of which lie a few 
centimetres distal to the dorsogluteal injection site.72  
 
There may also be modesty issues associated with the use of this 
site. 
1 to 3 ml Gluteus 
maximus 
  Vastus lateralis (lateral thigh)  
This site sits on the lateral (vastus lateralis) aspect of the thigh, part 
of a group of large, well-defined muscles in non-atrophied patients, 
the quadriceps femoris. Injections into this muscle produce a slower 
uptake of the medicine compared to the deltoid, but faster than 
gluteal muscles.69  
The site is easy to access. Femoral nerve injury due to inaccurate 
landmarking of the vastus lateralis site is rare but has been 
reported for analgesic injections post thigh surgery.73 




There are few disadvantages to using this site. It is relatively free of 
major nerves and blood vessels, the muscles are large 
and well defined, and the landmarks for administration are 
easy to locate.74,75 
Although it was once believed an additional advantage of this site 
was consistency of fat depth, original studies were in cadavers and 
more recent ultrasound research into obese men and women have 
found significant differences in fat depth here.56,57 
There may be modesty issues associated with the use of this site. 









NB. Zuclopenthixol acetate 50 mg in 1 ml (Clopixol Acuphase) is not intended for long term use. 
It is indicated for the short term management of acute psychosis, mania or exacerbations of 
chronic psychosis.67 
Please consult each product’s SmPC for for detailed prescribing information.
 
 
Maximum Volume for Oil-based Depot Administration into a Single Site 
Generic Name Brand/Trade Name Max Volume 
Flupentixol decanoate 20 mg in 1 ml Depixol Injection 3 ml65 
Flupentixol decanoate 100 mg in 1 ml Depixol Concentrate 2 ml65 
Flupentixol decanoate 200 mg in 1 ml Depixol Low Volume Injection 2 ml66 
Fluphenazine decanoate 100 mg in 1 ml 
(Modecate is no longer marketed in the UK 
but  an imported (unlicensed)  product 
containing 100 mg in 1 ml of fluphenazine 
decanoate may be obtained on a ‘named 
patient basis’ for those patients for whom 





in the SmPC13 
Fluphenazine decanoate 100 mg in 1 ml 
(Modecate is no longer marketed in the UK 
but  an imported (unlicensed)  product 
containing 25 mg in 1 ml of fluphenazine 
decanoate may be obtained on a ‘named 
patient basis’ for those patients for whom 
there is no alternative) 
 
Modecate Concentrate Injection 
 
Not specified 
in the SmPC13 
Haloperidol decanoate 50 mg in 1 ml Haldol Decanoate 50 mg in 1 ml 3 ml76 
Haloperidol decanoate 100 mg in 1 ml Haldol Decanoate 100 mg in 1 ml 3 ml76 
Pipotiazine palmitate 50 mg  in 1 ml 
(Piportil is no longer marketed in the UK 
but an imported (unlicensed) product 
containing 25 mg in 1 ml of pipotiazine 
palmitate may be obtained on a ‘named 
patient basis’ for those patients for whom 
there is no alternative) 
 
Piportil Depot 5% w/v Not specified 
in the SmPC77 
Zuclopenthixol decanoate 200 mg in 1 ml Clopixol Injection 2 ml68 







18.1 Good record keeping is essential for safe patient outcomes. 
 
18.2 The clinical record should reflect the registered practitioner’s full, chronological account 
of assessment, planning and care and provide information relevant to the procedure at the 
time of the administration of the injection. 
 
18.3 No action or omission by the registered practitioner must compromise patient safety; 
records must demonstrate this duty of care. The Nursing and Midwifery Council (NMC) Code 
and Professional Standards of Practice and Behaviour for Nurses, Midwives and Nursing 
Associates, and the professional guidance on the administration of medicines in healthcare 
settings by the Royal Pharmaceutical Society (RPS) and Royal College of Nursing (RCN) 
clearly outline expectations relating to record keeping and should be adhered to.4,5 
 
18.4 A registered practitioner administering an injection is required to following best practice 
in relation to record keeping as described below: 
 
• Record an accurate reflection of all discussions about informed choice and decisions   
made. 
 
• Ensure the assessment of the patient’s capacity to consent is assessed and that all legal 
requirements of the Mental Health Act are met. Both must be recorded. 
 
• Record the clinical intervention and specific references to any patient or carer concerns 
chronologically. 
 
• As a minimum, the patient’s clinical record must contain details of the date and time of the 
injection, the name of the medicine and dosage administered, the site of administration 
together with the registered practitioner’s signature and where applicable a signature 
from a second registered practitioner. These will normally be recorded on the prescription 
and administration record. If a student administers the injection under supervision then 
their signature must be countersigned by the supervising registered practitioner. 
 
• Any other comments that the patient or registered practitioner wish to be noted should 
also be recorded. 
 
• Any deviation from normal practice must be clearly recorded with the rationale for the 
clinical decision to do so. 
 
• Any untoward incident must be recorded in accordance with the local approved risk-
management reporting system.2,10 





19.1 All patients must have their long-acting antipsychotic injection treatment reviewed by the 
clinical team on a regular basis according to local guidelines. Such reviews should consider 
effectiveness, including any changes in symptoms and behaviour, side effects, adherence and 
physical health.7,8  
 
19.2 Such clinical reviews must be undertaken at least every 6 months in discussion with the 
patient, carer (where appropriate) and care team and will usually take place as part of the Care 
Programme Approach review. 
 
19.3 Prior to administration of the next scheduled injection, a discussion with the patient and an 
assessment of the previous injection site must be undertaken to ascertain if there are signs of 
swelling, pain, inflammation, infection or tissue damage. These are all clinical indicators that 
further physical assessment is urgently needed prior to any subsequent injection administration. 
 
19.4 Monitoring and evaluation must be undertaken in discussion with the patient and their carer 
(if appropriate) and should reflect a shared understanding of relapse plans and any concerns 
about treatment. 
 
19.5 The physical health of people with schizophrenia should be monitored at least once a year 
with particular attention to cardiovascular disease risk assessment.7,8 All organisations should 
have guidelines in place for this  which should also include specific monitoring requirements for 
injectable long-acting antipsychotic treatment. Appendix 4 outlines these. 
 
 







20.1 Clinical Audit is a part of the risk management process that supports using information 
positively to maintain good practice and to improve practice through learning from practice 
outcomes. The Nursing and Midwifery Council (NMC) requires nurses and registered 
nursing associates to work with colleagues to evaluate the quality of their work and that of 
the team and preserve the safety of those receiving care.4 
 
20.2 All untoward incidents that arise as a result of the care pathway within this document must 
be individually and collectively reviewed to provide sufficient knowledge to inform remedial 
action where necessary.10  
 
20.3 The NPSA (now NHS Improvement) advised healthcare organisations to undertake an 
audit of medicines practice relating to injections every year and develop an action plan to 
improve local practice as a result of this when necessary. A template to undertake this is 
available from: 
https://webarchive.nationalarchives.gov.uk/20171030131058/http://www.nrls.npsa.nhs.uk/reso
urces/type/alerts/?entryid45=59812&p=3. This audit should cover all aspects of practice and 
patient safety data for injectable medicines.6 
 
20.4 Organisations can use data from the Care Quality Commission’s national and local annual 
patient survey programme to identify any issues arising from patients’ experiences of medication 
management. 







21.1 There is a requirement that all registered practitioners involved in prescribing, preparing, 
administering and monitoring oil-based depot and other long-acting intramuscular antipsychotic 
injections receive training in order to be able to meet the expected level of competency and 
standards outlined to prevent harm to patients. This is made explicit by the NPSA (now NHS 
Improvement) guidance.6 
 
21.2 It is a requirement that all service provider organisations demonstrate evidence of how risks 
are managed in relation to training requirements for their staff if there could be a negative impact 
on service delivery, business continuity and/or patient or staff safety.2 
 
21.3 Training will be underpinned by the principles of patient experience, patient safety and 
efficient and effective delivery of care. Training should emphasise a person-centred approach, 
compassionate attitudes and a recognition that a positive patient experience will contribute to 














Clopixol Acuphase This is the short-acting formulation of zuclopenthixol injection intended for 
acute management of psychosis or mania. It should not be confused with the 
standard longer-acting zuclopenthixol depot injection as 
Acuphase releases the active zuclopenthixol much more quickly and 
more intensely and incorrect substitution could lead to severe adverse 
effects. 
Deltoid site The location for administration of injection into the deltoid muscle. 
Depot In mental health, this is the term used for oil-based, long-acting intra- 
muscular (IM) antipsychotic injections designed to be given by deep IM 
injection. They consist of the antipsychotic esterified to a decanoate or 
palmitate dissolved in an oily vehicle. The volume to be injected is  
deposited deep into the gluteal muscle and forms a depot from where it 
leaches over time according to its oil: water partition coefficient into the 
bloodstream. This, together with the time taken for circulating  
enzymes to hydrolyse the ester back to its active base, is responsible for the 
prolonged length of action of these formulations. 
Dorsogluteal site The location for administration of injection into the gluteus maximus muscle. 
Often referred to as the ‘upper outer quadrant of the buttock’. 
Excipient An inert substance necessarily incorporated into the formulation. Although 
these are selected to be inactive, the patient could be allergic to them or  
object to them on religious or cultural grounds. Details of all excipients are 
available in the relevant SmPC. 
First-pass  
metabolism 
This occurs following the absorption from the gut of a medicine that 
has been taken orally. A significant proportion of that medicine is  
metabolised by the liver, usually to an inactive by-product, on its ‘first pass’ 
through that organ. This reduces its bioavailability. 
Injection Administering a medicine into a patient’s body using a syringe and a 
needle. 
Inoculation incident Any incident where there is exposure to blood-borne viruses, this  
includes a blood splash or needle stick injury. 
Long-acting  
injection (LAI) 
In mental health, this is the term preferred for non-oil-based, long-acting 
intramuscular antipsychotic formulations such as aripiprazole (Abilify 
Maintena), olanzapine (ZypAdhera), paliperidone palmitate 1 monthly 
(Xeplion), paliperidone palmitate 3 monthly (Trevicta) and risperidone 
(Risperdal Consta) long-acting injections. The same careful injection technique 
is required to administer these products but their release characteristics are 
very different to each other as well as to oil-based formulations. 
Overage The additional volume added to an ampoule in order to enable the full volume 
required to be extracted. The overage is invariably higher for oily injections 
as they are much more viscous (thicker) than aqueous injections. Such 
overages vary between countries and the British overage for oily injections is, 
for example, smaller than the Danish overage. This is why zuclopenthixol 
(Clopixol) and flupentixol (Depixol) injections always seem generously filled. 





Rectus femoris The rectus femoris muscle of the anterior/lateral thigh (not recommended for 
intramuscular injections). 
Test dose An initial low dose of an oil-based depot antipsychotic injection which 
must be given to assess for tolerability to both the active ingredient and its vehicle 
or any other excipient. 
Vastus lateralis The lateral quadriceps muscle. 
Vehicle An inert liquid in which a medicine is dissolved or suspended. Although these are 
selected to be inactive, the patient could be allergic to them or object to them on 
religious or cultural grounds. (e.g. sesame oil, benzyl alcohol). Details of all vehicles 
are available in the relevant SmPCs. 
Ventrogluteal site The location for administration of injection into the gluteus medius and 
gluteus minimus. Colloquially referred to as the ‘hip site’. 
Z-tracking This is the recommended technique for all deep IM injections. it displaces superficial 
layers of skin and tissue creating a broken injection pathway (the z-track) containing 
the medicine in the intended target muscle and preventing it from moving back up 
the track to leak out at the skin surface.74 This has the advantage of achieving the 
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Appendix 1: Standard Operating Procedures (SOPs 1–6) 
This appendix contains six Standard Operating Procedures (SOPs) for the administration of 
oil-based depot and other long-acting antipsychotic injections.   
(These may be copied and used by any organisation or healthcare professional): 
 
SOP 1. General Preparation for Deep Intramuscular (IM) Injection 
 
SOP 2. Z-track Administration Technique 
 
SOP 3. Administration Technique for the Deltoid Site 
 
SOP 4. Administration Technique for the Dorsogluteal Site 
 
SOP 5. Administration Technique for the Ventrogluteal Site 
 
SOP 6. Administration Technique for the Vastus Lateralis site 
 
Appendix 2: Oil-based Depot and Other Long-Acting Intramuscular Antipsychotic Injections 
 
Appendix 3: Dose, Dosing Interval and Approximate Chlorpromazine Equivalents of Oil-
based Depot Antipsychotic Intramuscular Injections 
 
Appendix 4: Outline of Monitoring Requirements during Treatment with Long-acting 
Injectable Antipsychotics 
 
Appendix 5: Guidance on Missed Doses of Long-acting Injectable Antipsychotics 
 
Appendix 6: Dose Calculation Workbook 
 
 
Appendix 7: Questions to ask your Healthcare Professional 
                     (These may be copied and given to a patient or carer) 
 
Appendix 8: Human Factor Error Risk Reduction Checklist Template 
 
Appendix 9: An Audit Tool for Oil-based Depot and Other Long-Acting Intramuscular 










































































































































































Standard Operating Procedure 1 




Applicable to: Registered practitioners required to administer oil-based depots and 
other long-acting intramuscular antipsychotic injections in the course 
of their practice. 
 
Process 1 Wash your hands according to accepted hand cleansing technique and 





  15.10 Process 2 Check to see if the patient’s physical or mental health has changed 




Process 3 Ask about perceived benefit and any side effects experienced since the 
last injection – if this is not the first. 
12.2 
Process 4 Check to ensure: 
• The prescription is legal and valid. 
• The dose is due. 
• The dose has not already been given. 
• There are no contraindications or allergies. 






Process 5 Confirm that the patient has the capacity to consent and gives their 




Process 6 Prepare the injection making any necessary dose calculation and using 
the correct equipment. 
 13.3 
 14.1 
    14.10 
Process 7 Get a second registered practitioner, if available, to double check all 
items in processes 4, 5 & 7. 
 12.3 
Process 8 If a second registered practitioner is not available, ask the patient to 
check that the correct injection and dose is to be administered and that 
the injection is in date. 
 12.3 
Process 9 Choose the site of administration according to the licensed indication 
for the injection and in collaboration with the patient, proceed 







 Date of next 
review: 
 











Standard Operating Procedure 2 
Z-track Administration Technique 




Applicable to: Registered practitioners required to administer oil-based depots and 
other long-acting intramuscular antipsychotic injections in the course of 




Process 1 Pull the skin in the target area taut and to one side with either the 
thumb or side of the non-dominant hand and maintain this firm traction 
of the skin throughout the procedure.74 
 
Process 2 Insert the needle with a darting motion at 90 degrees to the skin 
surface to an adequate depth to allow the needle to penetrate the 




Process 3 For dorsogluteal injections only – for all other sites where there are 
no major blood vessels below the injection site, this is unnecessary69 
so go to Process 4. 
 
Steady the barrel of the syringe with the remaining fingers of the non-
dominant hand and pull back on the plunger with the dominant hand 
to aspirate. Should blood appear in the syringe all the equipment 
must be discarded and the whole procedure started again.74 If no 
blood appears, it is safe to continue. 
 
Process 4 Depress the plunger slowly (1 ml per 10 seconds) to allow the 
muscle fibres to expand to accommodate the drug.74 
 
Process 5 Wait a further 10 seconds before removing the needle and once it has 
been removed, only then release the traction on the skin.55 
 
Process 6 If necessary, the injection site may be wiped with a dry gauze swab.  
Process 7 A plaster may be applied if this is the patient’s choice and if they have 



































Figure 2: Z-track Technique 







Standard Operating Procedure 3 
Administration Technique for the Deltoid Site 





Applicable to: Registered practitioners required to administer a long-acting 
intramuscular antipsychotic injection at the deltoid site in the course of 
their practice. 
 
Process 1 Ask the patient to sit down and loosen their clothes so their arm and 
shoulder are exposed. Ask them to position their arm across their body 
to relax the muscles (Fig 3a). 
  
Process 2 Follow processes 1–9 in SOP 1.  
Process 3 Palpate the upper arm and find the landmarks of the acromion process 
and the axilla. The target injection site can be located by visualising an 
inverted triangle which extends from the base of the acromion process 
and extends down to a point level with the axilla. Now form a rectangle 
within the original triangle by placing two fingers below the acromion 
process to form the top edge of the rectangle and with the bottom edge 
level with the axilla. The side edges should be parallel to the arm. The 
injection site is in the middle of this visualised rectangle (Figs 3d & 3e).74 
 
Process 4 Clean the skin if necessary with soap and water or according to local 
policy. 
13.5 
Process 5 Administer the injection using a Z-track technique (SOP 2) (Fig 2). 17.5 
Process 6 Dispose of all equipment immediately with safe disposal of sharps 
into an appropriate, puncture proof, correctly labelled sharps bin. 
Do not re-sheath needle. 
15.6 
15.7 
Process 7 Document on the prescription/administration chart and in the clinical 
record the date, time and dose of medication administered, injection site 
and side of the body plus any deviation from standard practice with a 
rationale for the clinical decision to do so. 
18.4 
Process 8 Exchange information about monitoring arrangements, how to 
manage common side effects and what to do if the patient 
experiences any change to their mental or physical health status 
before the next clinical contact. 
19.4 
Process 9 Remove personal protective equipment including gloves and wash 






















Administration Technique for the Deltoid Site 
Figure 3a 
Figure 3d Figure 3e 
Deltoid muscle                      
----1 
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Standard Operating Procedure 4 
Administration Technique for the Dorsogluteal Site 




Applicable to: Registered practitioners required to administer a long-acting  
intramuscular antipsychotic injection at the dorsogluteal site in 
the course of their practice. 
 
Process 1 Follow processes 1–9 in SOP 1.  
Process 2 Ask the patient to lie down and loosen their clothes so one 
buttock is exposed. Ask them to either lie on their front or side 
with the femur internally rotated to minimise pain on 
administration (Fig 4a). 
13.2 
13.3 
Process 3 If a syringe and/or needle is provided in the product pack by the 
manufacturer this MUST be used. If not select an appropriate 
needle length to reach the gluteus muscle. Consider the Body 
Mass Index (BMI) and gender of the patient. In obese patients 
with a BMI of 30 or more, a 51mm needle or alternative injection 
site may be required.   
14.1–14.10 
Process 4 Draw an imaginary cross onto one buttock and identify the upper 
outer quadrant. Divide this first quadrant into quarters.  
The injection site is located within the upper outer quadrant of 
the upper outer quadrant, approximately 5 cm to 7.5 cm below 
the iliac crest (Fig 4e).74 
 
Process 5 Clean the skin only if necessary, with soap and water or  
according to local policy. 
13.5 
Process 6 Administer the injection using a Z-track technique (SOP 2) (Figs 2 
& 4f). 
17.5 
Process 7 Dispose of equipment immediately with safe disposal of sharps 
into an appropriate, puncture-proof, correctly labelled sharps 
bin. Do not re-sheath needle. 
15.6 
15.7 
Process 8 Document on the prescription/administration chart and in the 
clinical notes record the date, time and dose of medication 
administered, injection site and side of the body plus any 
deviation from standard practice with rationale for the clinical 
decision to do so. 
18.4 
Process 9 Exchange information about monitoring arrangements, how to 
manage common side effects and what to do if the patient 
experiences any change to their mental or physical health status 
before the next clinical contact. 
19.4 
 
Process 10 Remove personal protective equipment including gloves and 


















Administration Technique for the Dorsogluteal Site  
Figure 4a 
Figure 4d 
Figure 4e Figure 4f 
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Standard Operating Procedure 5 
Administration Technique for the Ventrogluteal Site 





Applicable to: Registered practitioners required to administer a long-acting 
intramuscular antipsychotic injection at the ventrogluteal site in the 
course of their practice. 
 
Process 1 Follow processes 1–9 in SOP 1.  
Process 2 Ask the patient to lie down on their side and expose their hip (Fig 5a). 13.2 
13.3 
Process 3 Palpate the greater trochanter (Fig 5d). Place the heel of the opposite 
hand to the patient’s leg on the greater trochanter (i.e. your left hand 
on their right leg or vice versa). Locate and place index finger on the 
anterior superior ileac spine and travel along it until your index finger 
is in line with the vertical axis of the body. Your thumb should be 
pointing towards the front of the leg. Spread the middle finger to 
form a ‘V’. The injection site is in the middle of this ‘V’, level with the 
first knuckles of your fingers (i.e. proximal interphalangeal joints)  
(Fig 5d).75 
 
Process 4 Visualise the site and remove your hand to prevent needle stick 
injury. 
 
Process 5 Clean the skin only if necessary with soap and water or according to 
local policy. 
13.5 
Process 6 Administer the injection using a Z-track technique (SOP 2) (Fig 2). 17.5 
Process 7 Dispose of equipment immediately with safe disposal of sharps into 




Process 8 Document on the prescription/administration chart and in the clinical 
record the date, time and dose of medication administered, injection 
site and side of the body plus any deviation from standard practice 
with a rationale for the clinical decision to do so. 
18.4 
Process 9 Exchange information about monitoring arrangements, how to 
manage common side effects and what to do if the patient 
experiences any change to their mental or physical health status 
before the next clinical contact. 
19.4 
Process 10 Remove personal protective equipment including gloves and wash 










































Standard Operating Procedure 6 
Administration Technique for the Vastus Lateralis site  





Applicable to: Registered practitioners required to administer a long-acting 
intramuscular antipsychotic injection at the vastus lateralis site in the 
course of their practice. 
 
 
Process 1 Follow processes 1–9 in SOP 1.  
 





Process 3 The vastus lateralis site targets the lateral side of the  
quadriceps femoris group of muscles and is situated in the anterior 
lateral aspect of the thigh. It is located by placing the little finger of one 
hand on the lateral femoral condyle of the knee and the little finger of 
the other hand on the greater trochanter. Now try to touch both 
thumbs together. Both hands are then spanning the distance and the 
injection site is at the midpoint (Fig 6e).74  
 
 
Process 4 Visualise the site and remove your hand to prevent needle stick injury.  
 




Process 6 Administer the injection using a Z-track technique (SOP 2) (Fig 2). 17.5 
 
Process 7 Dispose of equipment immediately with safe disposal of sharps into 






Process 8 Document on the prescription/administration chart and in the clinical 
record the date, time and dose of medication administered, injection 
site and side of the body plus any deviation from standard practice 
with a rationale for the clinical decision to do so. 
18.4 
 
Process 9 Exchange information about monitoring arrangements, how to manage 
common side effects and what to do if the patient experiences any 
change to their mental or physical health status before the next clinical 
contact. 
19.4 
Process 10 Remove personal protective equipment including gloves and wash your 
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Administration Technique for the Vastus Lateralis Site
















   Oil-Based Depot Intramuscular Antipsychotic Injections 
 
General note: The viscosity of all oil-based injections is reduced at warmer temperatures; i.e. they will become less sticky and easier to draw up and administer when close to body temperature. The viscosity 
(thickness) of sesame oil is higher (thicker) than thin vegetable oil. 
Antipsychotic Generic Name  
and Formulation 
UK Brand Name Standard Dose Range for 
Adult Maintenance Treatment 
 
 Practice Points 
Flupentixol decanoate65,66 
In thin vegetable oil (derived from coconuts) 
 
Depixol Injection: 20 mg in 1 ml 
Depixol Concentrate Injection: 100 mg in 1 ml 
Depixol Low Volume Injection: 200 mg in 1 ml 
50 mg every 4 weeks to 
300 mg every 2 weeks 
BNF Max: 400 mg weekly 
Route: Deep intramuscular injection into the upper outer buttock (dorsogluteal) or 
lateral thigh (vastus lateralis) 
• The maximum volume into a single site should not exceed 2 ml 
• A test dose of 20 mg is indicated 
 Fluphenazine decanoate13 In sesame oil 
Modecatel is no longer marketed in the UK but  an 
imported (unlicensed) products containing 25 mg in 
 1 ml  and 100 mg in 1 ml of fluphenazine 
decanoate are available  on a ‘named patient 
basis’ for those patients for whom there is no 
alternative 
Modecate Injection: 25 mg in 1 ml  
Modecate Conc. Injection: 100 mg in 1 ml 
 
12.5 mg (6.25 mg for patients 
over 60) to 100 mg every 2–5 weeks 
Route: Deep intramuscular injection into the gluteal region 
• A test dose of 12.5 mg (6.25 mg in the elderly) is indicated 
 
Haloperidol decanoate76 In sesame oil Haldol decanoate: 50 mg in 1 ml 
Haldol decanoate: 100 mg in 1 ml 
 
50 mg every 4 weeks 
to 300 mg every 4 weeks 
If 2-weekly administration is 
preferred, these doses should be 
halved 
Route: Deep intramuscular injection into the gluteal region using an appropriate 
needle, preferably 2–2.5 inches long, of at least 21 gauge 
• A test dose of 25 mg (12.5 mg in the elderly) is indicated 
Pipotiazine palmitate77 In sesame oil 
Piportil  is no longer marketed in the UK but an  
imported (unlicensed) product containing 25 mg in 
   1 ml  of pipotiazine palmitate is available  on a   
‘named patient basis’ for those patients for whom 
there is no alternative 
 
Piportil Depot 5% w/v (50 mg in 1 ml) 
 
50 mg (5–10 mg in elderly) to 
100 mg every 4 weeks 
 
BNF max. 200 mg every 4 weeks 
Route: Deep intramuscular injection into the gluteal region 
 
• A test dose of 25 mg (5–10 mg in elderly) is indicated 
 
Zuclopenthixol decanoate68      
In thin vegetable oil (derived from coconuts) 
Clopixol Injection(200 mg in 1 ml) 
Clopixol Conc. Injection (500 mg in 1 ml) 
200 mg to 500 mg every 1–4 weeks 
  
BNF Max: 600 mg every week 
Route: Deep intramuscular injection into the upper outer buttock (dorsogluteal) or 
lateral thigh (vastus lateralis) 
• The maximum volume into a single site should not exceed 2 ml 
• A test dose of 100 mg (25–50 mg in the elderly) is indicated 
 
 






   Other Long-Acting Intramuscular Antipsychotic Injections 
  
Antipsychotic Generic Name  
and Formulation 
UK Brand Name Standard Dose Range for 





Powder and solvent for 
prolonged-release  




















400 mg & 300 mg 
 













400 mg monthly 
 
Route: Deep intramuscular injection into either the gluteal or the deltoid muscle 
• Patients should normally be initially successfully treated with oral aripiprazole before receiving the long-
acting injection in order to establish tolerability and response 
• Initial dose titration is not required 
• It should be administered once monthly as a single injection (no sooner than 26 days after the previous 
injection). Detailed instructions regarding missed doses are provided in the SmPC  
• After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 
consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy 





Powder and solvent for 
prolonged release  
suspension for deep 
intramuscular injection 
ZypAdhera 210 mg 
ZypAdhera 300 mg 
ZypAdhera 405 mg  
 
Powder and solvent for prolonged release 
suspension for deep intramuscular 
injection. 
 
When reconstituted with the supplied 
solvent all vials provide a final 
concentration of 150 mg olanzapine per  
1 ml. Hence for a 150 mg dose 1 ml of a 
reconstituted vial is administered. For 
economic reasons to reduce wastage this 
should always be the 210 mg preparation 
 
150 mg – 300 mg olanzapine 
every 2 weeks 
 
Doses may be adjusted to allow a 4-
weekly frequency noting that 405 mg 4-
weekly substitutes for 210 mg 2-weekly 
regimen 
Route: Deep intramuscular gluteal injection 
• Only needles supplied in the dose pack should be used 
• Online training provided by the manufacturer is available to practitioners unfamiliar with this product 
• Fractions of a dose may not be administered 
• Patients should be initially successfully treated with oral olanzapine before receiving the long-acting 
injection in order to establish tolerability and response. 
• A dosing table in the SmPC provides the information for equivalent long-acting IM dose to oral regimen 
in place   
• Fractions of a dose may not be administered 
• The initiation of long-acting IM olanzapine should be made without recourse to cross-tapering of oral 
medication. Although this may feel counter-intuitive, non-oil-based long-acting antipsychotics must 
be seen as products with discrete pharmacokinetic properties 
• After each injection, patients must be observed for post-injection syndrome (signs and symptoms 
consistent with olanzapine overdose) in a healthcare facility by appropriately qualified personnel for at 






Antipsychotic Generic Name  
and Formulation 
UK Brand Name Standard Dose Range for 




Palmitate16    (PP1M) 
 
Prolonged-release suspension for 
injection 
Xeplion 50 mg 
Xeplion 75 mg 
Xeplion 100 mg 
Xeplion 150 mg 
 
Supplied in pre-filled syringes 
Initiation: 
Day 1: 150 mg into the deltoid muscle 
Day 8: 100 mg into the deltoid 
muscle 
One month later: 
75 mg – 150 mg according to clinical 
need into either the deltoid or gluteal 
muscles. 
Thereafter: once a calendar month (not 
28 days) 
Route: By deep IM injection. The Day 1 and Day 8 initiation doses must each be administered into the deltoid 
muscle in order to attain therapeutic plasma concentrations rapidly. Following the second dose, monthly 
maintenance doses can be administered in either the deltoid or gluteal muscle 
• A switch from gluteal to deltoid (and vice versa) should be considered in the event of injection site 
pain if the discomfort is not acceptable. It is also recommended to alternate between left and right 
sides. Fractions of a dose should not be administered 
• Only needles supplied in the dose pack should be used 
• Fractions of a dose may not be administered. 
Paliperidone  
Palmitate17    (PP3M) 
 
 
Prolonged-release suspension for 
injection every 3 months17 
Trevicta 175 mg  
Trevicta 263 mg 
Trevicta 350 mg  
Trevicta 525 mg  
 
Prolonged-release suspension of 
paliperidone for injection in pre-
filled syringes                              
Dosing is based on the last dose of one 
monthly paliperidone injection using a 
3.5-fold higher dose 
 
 A dosing table is available in the SmPC17 
 
 
Route: Deep intramuscular injection into either the gluteal or the deltoid muscle. Only needles supplied 
by the manufacturer should be used 
• Detailed instructions regarding missed doses are provided in the SmPC  
• If needed, dose adjustment can be made every 3 months in increments within the range of 175 mg to 
525 mg based on individual patient tolerability and/or efficacy 
• Due to the long-acting nature of this formulation the patient’s response to an adjusted dose may not 
be apparent, if the patient remains symptomatic, they should be managed according to clinical 
practice  
• To avoid incomplete administration, the pre-filled syringe must be shaken vigorously for at least 15 
seconds within 5 minutes prior to administration to ensure a homogeneous suspension. In the event of 
an incompletely injected dose, the dose remaining in the syringe should not be re-injected and another 
 dose should not be given since it is difficult to estimate the proportion of the dose actually 
administered. The patient should be closely monitored and managed as clinically appropriate until the 
next scheduled 3- monthly injection 
• Details regarding what should be done when doses are missed may be found in the SmPC 





Generic Name and Formulation 
UK Brand Name Standard dose range for 




Powder and solvent for prolonged-
release suspension for intramuscular 
injection 
Risperdal Consta 25 mg 
Risperdal Consta 37.5 mg 
Risperdal Consta 50 mg 
 
Powder and solvent for prolonged-
release suspension for deep 
intramuscular injection 
 
Also available in pre-filled syringes to 
save reconstitution 
 
25 mg to 50 mg every 2 weeks 
 
BNF Max. Dose: 
50 mg every 2 weeks 
Route: Deep intramuscular gluteal or deltoid injection using either the supplied 20g 50 mm safety needle 
(gluteal) or the 21g 25 mm safety needle (deltoid) also supplied. Injections should alternate between 
buttocks or right and left arms 
• Only needles supplied in the dose pack should be used 
• Refrigerated storage and maintenance of the cold chain is essential until administration 
• A test dose is not indicated but tolerability and efficacy of oral risperidone must be confirmed 
before treatment is initiated 
• Fractions of a dose may not be administered 
• The maximum volume that may be administered in to one site is less restrictive but for overall 
comfort not more than single diluent volume should be injected in to any one site. When 
administering doses above 50 mg (unlicensed) it is considered acceptable practice by the authors to 
use the reconstituted higher-strength injection as a diluent for the second vial 
• After a single intramuscular injection, the release profile consists of a small initial release of 
risperidone (<1% of the dose), followed by a lag time of 3 weeks. The main release of risperidone 
starts from week 3 onwards, is maintained from 4 to 6 weeks, and subsides by week 7. Oral 
antipsychotic supplementation should therefore be given during the first 3 weeks of treatment 
• The combination of the release profile and the dosage regimen (intramuscular injection every 2 
weeks) results in sustained therapeutic plasma concentrations.  





















































Approximate Dose Equivalent to Chlorpromazine 100 mg a day78 
  
Range of Values from the Literature78 
Flupentixol decanoate Depixol 40 mg 2-weekly 10 mg per week 10–20 mg per week 
Fluphenazine decanoate Modecate 25 mg 2-weekly 5 mg per week 1–12.5 mg per week 
Haloperidol decanoate Haldol 100 mg 4-weekly 15 mg per week 
 
(500 mg of chlorpromazine a day is equivalent to 100 mg of haloperidol 
decanoate monthly) 
 
(25 mg of fluphenazine decanoate  
2-weekly or 40 mg of flupentixol decanoate 2-weekly is equivalent to 100 mg 
of haloperidol decanoate monthly) 
5–25 mg per week 
Pipotiazine palmitate 
(No longer marketed in the UK 
but imported on a ‘Named 
Patient Basis’ for those patients 
for whom there is no alternative) 
 
Piportil 50 mg 4-weekly 10 mg per week 10–12.5 mg per week 





Appendix 4: Outline of Monitoring Requirements during Treatment with Long-acting Injectable Antipsychotics.7,8,12,19,79,80,81,82,83     
 
 













to include waist circumference or hip to 
waist ratio and Body Mass Index (BMI) 
calculation where possible 
• Some antipsychotic have the potential to cause weight gain 
• This can contribute to increased cardiovascular (CV) risk and metabolic problems 
✓ 
Then weekly 
for the first 6 
weeks 
✓ ✓ 
Urea & electrolytes 
including creatinine or estimated 
Glomerular Filtration Rate (GFR) 
• Renal impairment can reduce the capacity to excrete certain medicines and a dose 
reduction may be necessary 







(Total cholesterol, HDL, cholesterol, 
Total/HDH–cholesterol ratio. 
Triglycerides) -a fasting sample if 
possible 
• Some antipsychotics can cause small adverse changes in lipid profiles which can 
contribute to CV risk and metabolic problems 





Liver Function  
(bilirubin, alkaline phosphatase, ALT, 
albumin, total protein, gamma-GT) 
• Hepatic impairment can reduce the ability to metabolise certain medicines and a dose 
reduction may be necessary 
• Drug-induced liver damage can be due to direct dose-related hepatotoxicity or 
hypersensitivity. 







Full blood count • Some antipsychotics can cause blood dyscrasias such as agranulocytosis and 
leukopenia 
✓  ✓ 
Blood Glucose:  – fasting if possible 
or preferably glycated haemoglobin 
(HbA1c) 
• Some antipsychotics can increase the risk of developing diabetes ✓  ✓ 
Prolactin • Some antipsychotics can increase prolactin levels leading to gynaecomastia, 
galactorrhoea, amenorrhoea and sexual dysfunction and a possible increased risk of 
osteoporosis 




Appendix 4 continued: Outline of Monitoring Requirements during Treatment with Long-acting Injectable Antipsychotics 
 









Blood pressure (Sitting/lying and 
standing and pulse) 
• Some antipsychotics can cause hypotension particularly during initiation  
• Factors that can influence/ indicate  CV risk should be monitored regularly 
✓ also  during 
dose increase 
✓ 
Alcohol intake • High alcohol intake is associated with multiple physical and mental health risks ✓  ✓ 
Smoking status • Smoking is associated with CV risk ✓  ✓ 
Review of effectiveness, side effects, 
adherence 
• Before initiation of treatment it should be ascertained which side effects the patient 
is least willing to tolerate. 
• On review any side effects experienced should be assessed including: 
        extrapyramidal side effects (EPSE): akathisia, dystonia and tardive dyskinesia 
(TD) plus sedation- common, palpitations – less common 
• The Glasgow Antipsychotic Side-effect Scale (GASS) may be of use84  
• Effectiveness of treatment should be regularly reviewed 
• Whilst non-adherence is more easily identified with a long acting injection some oral 
formulations may be co-prescribed and adherence with these should be confirmed 
where possible 










          
      ✓ 
✓ 
Electrocardiograph (ECG) • Certain antipsychotics have been associated with ECG changes, some of which may be linked to QT prolongation 
• All inpatients should have an ECG on admission 
• Long stay patients and those living in the community should have an ECG at baseline and annually when there are clinical indications such 
as 
         - a personal history of CV Disease e.g. known ischaemic/structural heart disease, QT prolongation etc. 
         - CV risk factors identified in a physical examination  
         - the SmPC of the antipsychotic prescribed requires ECG monitoring e.g. Haloperidol decanoate76 
              -- ‘high dose antipsychotic therapy’ (HDAT) is prescribed79  
           - if other medicines known to cause ECG abnormalities are co-prescribed e.g. tricyclic antidepressants,  anticholinergics, 
erythromycin, anti-arrhythmics etc. 
• If other factors have been identified which may predispose an individual to arrhythmias such as  
        - electrolyte abnormalities such as hypokalaemia, hypocalcaemia, hypomagnesaemia 
        - organic disease such as liver disease, renal disease, hypothyroidism 
General physical health enquiry  •  Monitoring provides an opportunity for intervention regarding sexual health, 
contraception, pregnancy, oral and eye health, nutritional status, diet and physical 
activity, use of illicit substances/ non-prescribed medicines and vaccination status.  












It is always good practice to consult relevant product SmPC while dealing with missed doses.  
 
 
Aripiprazole LAI (Abilify Maintena)14 
 
If 2nd or 3rd dose is missed and time 
since last injection is: 
Action 
> 4 weeks and < 5 weeks The injection should be administered as soon as possible and 
then resume monthly injection schedule. 
> 5 weeks Concomitant oral aripiprazole should be restarted for 14 days with 
next administered injection and then resume monthly injection 
schedule. 
If 4th or subsequent doses are missed 
(i.e., after attainment of steady 
state) and time since last injection is: 
Action 
> 4 weeks and < 6 weeks The injection should be administered as soon as possible and then 
resume monthly injection schedule. 
> 6 weeks Concomitant oral aripiprazole should be restarted for 14 days with 
next administered injection and then resume monthly injection 
schedule. 
 
Paliperidone 1-monthly LAI (Xeplion) PP1M16 
 
2nd initiation dose (100mg) and 
time since last injection is: 
Action 
< 4 weeks 100mg should be injected into the deltoid muscle as soon as possible. 
A third paliperidone injection of 75 mg (deltoid or gluteal) should be 
administered 5 weeks after the first injection (regardless of the timing 
of the second injection). 
The normal monthly cycle of injections in either the deltoid or gluteal 
muscle of 50mg to 150mg based on patient tolerability and/or efficacy 
should be followed thereafter. 
> 4 weeks and < 7 weeks Day 1 - 100mg deltoid injection asap 
Day 8 - 100mg deltoid injection 
Day 36 - resume the normal monthly cycle of injections (deltoid or 
gluteal) based on patient tolerability and/or efficacy. 
> 7 weeks Day 1 - 50mg deltoid injection asap 
Day 8 - 100mg deltoid injection 
Day 36 - Resume the normal monthly cycle of injections (deltoid or 
gluteal) based on patient tolerability and/or efficacy. 
Monthly maintenance dose and 
time since last injection is: 
Action 
< 6 weeks Administer depot as soon as possible 
> 6 weeks and < 6 months 50mg – 100mg: 
Day 1 - deltoid injection at same dose patient was previously stabilised on 
asap 
Day 8 - another deltoid injection (same dose) 
Day 36 - resume the normal monthly cycle of injections (deltoid or 
gluteal) based on individual patient 
tolerability and /or efficacy. 
150mg: 
Day 1 - 100mg deltoid injection asap 
Day 8 - 100mg deltoid injection 
Day 36 - resume the normal monthly cycle of injections (deltoid or 
gluteal) based on individual patient tolerability and/or efficacy. 
> 6 months Day 1 - 150mg deltoid injection asap 
Day 8 - 100mg deltoid injection 
Day 36 - resume the normal monthly cycle of injections (deltoid or 














It is always good practice to consult relevant product SmPC while dealing with missed doses.  
 
 
Paliperidone 3-monthly LAI (Trevicta) PP3M17 
 
If scheduled dose is missed and the time 
since last injection is: 
Action 
> 3½ months up to 4 months The injection should be administered as soon as possible and 
then resume the 3-monthly injection schedule. 
4 months to 9 months Use the recommended re-initiation regimen shown in the 
table below. 
> 9 months Re-initiate treatment with 1-monthly paliperidone palmitate 
injectable as described in the prescribing information for that 
product. 
TREVICTA can then be resumed after the patient has been 
adequately treated with 1-monthly paliperidone palmitate 
injectable preferably for four months or more. 
 
 
Recommended re-initiation regimen after missing 4 months to 9 months of paliperidone 3-
monthly LAI (Trevicta) PP3M17 
 
If the last dose of 
Trevicta was: 
Administer 1-monthly paliperidone palmitate 




deltoid or gluteal 
muscle) 
Day 1 Day 2 1 month after day 8 
175 mg 50 mg 50 mg 175 mg 
263 mg 75 mg 75 mg 263 mg 
350 mg 100 mg 100 mg 350 mg 
525 mg 100 mg 100 mg 525 mg 
 
Risperidone LAI (Risperdal Consta)18 
 
Time since last 
injection 
What happens to risperidone 
plasma levels 
Plan 
2-6 weeks Therapeutic risperidone plasma 
levels remain 
Administer depot asap 
> 6 weeks 
but < 7 weeks 
Risperidone plasma level starts to 
decrease and may become sub-
therapeutic after a further 1-3 
weeks 
Administer depot as usual but 
monitor mental state closely and, if 
necessary, give oral risperidone 
> 8-9 weeks All risperidone will have been 
eliminated from the body 
Administer depot asap and give oral 
risperidone for at least 3 weeks 
until plasma level becomes 
therapeutic again 
 
Olanzapine LAI (ZypAdhera)15 
The absorption half-life for olanzapine LAI is 30 days. Therefore, each injection releases measurable 




The manufacturer of ZypAdhera does not provide advice on missed doses. 
 
Guidance supplied and reproduced with permission from Professor David Taylor, South London & Maudsley 
NHS Foundation Trust.85
Target oral olanzapine 
dose 
Recommended starting dose 
of ZypAdhera 
Maintenance dose after 2 
months of ZypAdhera 
treatment 
10 mg/day 210 mg/2 weeks or 405 mg /4 
weeks 
150 mg/2 weeks or 300 mg/4 
weeks 
15 mg/day 300 mg/2 weeks 210 mg/2 weeks or 405 mg/4 
weeks 
20 mg/day 300 mg/2 weeks 300 mg/2 weeks 
Appendix 5 continued: Guidance on Missed Doses of Long-   









Test Dose Calculations for Oil-Based Depot Intramuscular Antipsychotic Injections 
 
For oil-based depot intramuscular antipsychotic injections it is good practice to give a test 
dose before treatment is initiated to assess for tolerability to both the active ingredient as 
well as to the oily vehicle. Occasionally patients with nut allergy may react to the oil. If a full 
dose is given from the outset then patients may experience more severe, protracted 
discomfort. 
 
How much? A worked example: 
 
The amount recommended for a test dose is stated by the manufacturer in the Summary of 
Product Characteristics (SmPC)11 and in the British National Formulary (BNF).12 A 





The test dose of flupentixol decanoate for an adult is 10 mg 
 
Flupentixol decanoate is available in ampoules containing 20 mg in 1 ml 
 
10 mg is therefore contained in 1/20 x 10 = ½ ml = 0.5 ml 
 
Thus to give a 10 mg test dose of flupentixol decanoate, 0.5 ml of the solution containing 
20 mg in 1 ml is required 
 
Try this example yourself: 
 
The test dose of zuclopenthixol decanoate is 50 mg 
 
Zuclopenthixol decanoate is available in 1 ml ampoules containing 200 mg in 1 ml and you 




















To give a 50 mg test dose of zuclopenthixol decanoate, 0.25 ml of a solution containing 
200 mg in 1 ml is required. 
 
If you have the correct answer could you show a colleague how you worked it out? 





The line statement method is a good way to reassure both yourself and a second person 
of how the correct answer was reached: 
 
 
Start with the product in front of you: 200 mg in 1 ml 
 
                                                 ÷ 2   =          100 mg in 0.5 ml 
 
                                                 ÷ 2   =          50 mg in 0.25 ml 
 
 
With this method you will see that whatever you do to the left-hand side in terms of a 
mathematical application you do to the right-hand side. This principle never changes however 
hard the figures may look. 
 
 
Try this next example: 
 
What volume of zuclopenthixol decanoate is required to administer a 350 mg dose using the 



















To give a 350 mg dose of zuclopenthixol decanoate, 1.75 ml of a solution containing 200 mg 
in 
1 ml is required. 
 
The line statement method is a good way to reassure both yourself and a second person 
of how the correct answer was reached: 
 
Line 1:        You start with: 200 mg in 1 
ml 
 
Line 2:        ÷ 2 = 100 mg in 0.5 ml  
Line 3:        ÷ 2 =   50 mg in 0.25 ml  
You need 350 mg: 350 ÷ 50 = 7 
Multiply line 3 by 7 because 7 x 50 mg = 350 
mg 
 
350 mg = 7 x 0.25 = 1.75 ml 
 





For those who prefer a different way and/or like algebra we can identify a generic equation for 
this process: 
 
Imagine you have an ampoule containing X mg of antipsychotic in 1 ml 
You are required to administer a dose of Y mg, and you need to know the volume to draw up 
The volume required = Y x the volume X mg is contained in X 
 
Putting the figures from the previous example into this equation: 
 
The volume required = 350 x 1 =  1.75 ml 
                                        200 
 
 
Based on a real scenario from clinical practice look at the following depot prescription and 
identify the dose volume required and consider how you would respond to the following 
prescription.                                 
                                                     Rx Depixol 37.5 mg 2-weekly 
 
What volume is required to administer this dose? Work out your answer in the box below: 
 



























÷ 2 5 mg in 0.25 ml line 3 
÷ 2 2.5 mg in 0.125 ml line 4 
Multiply line 2 by 3 30 mg in 1.5 ml line 5 
Add line 3 5 mg in 0.25 ml line 6 
Add line 4 2.5 mg in 0.125 ml line 7 
Add lines 5,6 & 7 37.5 mg in 1.875 ml  
37.5 mg of flupentixol decanoate (Depixol) is contained in 1.875 ml of a solution containing 20 
mg in 1 ml (or 0.375 ml of the solution containing 100 mg in 1 ml). 
 
However, neither of these is an accurately measurable volume and the prescription should be 
referred back to the prescriber for review.  Although depot dosing is not an exact science, 
approximating impossible volumes is not good medicines management. 
 
Please note that long-acting injections of olanzapine, paliperidone and risperidone are all 
supplied as dose packs and the entire contents of the ampoule should be injected according to 






The professionals working in partnership with you must give you enough information when 
planning your care for you to be able to make informed choices about your treatment. They 
should anticipate your needs and try to design your care with these in mind. 
 
Before your appointments it may help if you write down some of the questions you might want 
to ask as you think of them. You may wish to include your carers or relatives in talking through 
what would be helpful to you. 
 
Some of the things you may wish to consider asking could include: 
 
 
• What is a depot injection? 
 
• What is a long-acting antipsychotic injection and do these differ from depots? 
 
• How are these different to my tablets? 
 
• How does a depot injection work? 
 
• How does a long-acting injection work? 
 
• What side effects will I have and will they be worse than taking tablets? 
 
• How will I change over from tablets to injections? 
 
• How often will I need an injection? 
 
• Will I need to have it for the rest of my life? 
 
• Can I have the injection at home or will it be given somewhere else? 
 
• Will I need to get undressed? 
 
• Can I give myself this injection? 
 
• What benefit will I have as a result of swapping from tablets to an injection? 
 
• Are there any risks I need to know about? 
 
• Are there any risks at the time of the injection being given to me and will it hurt? 
 
• How will having an injection affect my life and make me feel? 
 
• Will it make me tired? 
 
• Will I be able to drive my car and operate machinery at work? 
 
• Do I have to tell my employer about this treatment? 
 
• Will the injection affect my sleep? 
 
• Will it affect my sex life? 
 
• If I don’t want to accept an injection, what will this mean for my care? 
 
• If I do accept treatment by injection, can I change my mind if I don’t like it at any time? 
 
• Can you give me an injection against my wishes? 
Appendix 7: Questions to ask your Healthcare Professional  





Human Factor Error Risk  
Reduction Checklist for the  
Administration of a 
Long-Acting Intramuscular 
Injection 












Assessment of capacity to consent Legal requirement   
Read the patient’s clinical record Need up-to-date clinical 
knowledge of patient 
  
Check there are no changes to the patient’s 
health that require review 




Check the patient understands all the 
information relevant to  
treatment and has the capacity to confirm 
their decision to proceed 
Compliance with the legal 
requirements of the Mental Health 
Capacity Act 2005 
  
The capacity of the patient is  
confirmed and recorded 
Their capacity may change 
between injections and needs to 
be confirmed 
  
The prescription is accurate and conforms 
with the local Medicines Code 
Prescription inaccuracy will place 
both patient and practitioner at risk 
  
Ask the patient when their last  
injection was given 
Cross check that the current 
injection has not already been given 
and that the prescription and or 
clinical notes were not signed in 
error 
  
The product licence for the 
 injection is for the site planned 
Not all injections are for use in all 
muscle groups or injection sites 
  
Hand hygiene observed before 
and after patient contact. Use   
disposable gloves, apron and eye 
protection where appropriate 
Prevention of infection   
Medical devices assembled in  
accordance with non-touch  
technique 
Prevention of infection   
Read the label, check the injection is in date 
and cross check the label against the 
prescription 
Confirm the right medicine, right 
dose, right frequency, right patient, 
right formulation, right route, right 
time 
  
Check any calculation of dose  
volume 
Reduces the risk of the wrong dose 
being administered 
  
Check the patient’s allergy status Reduces the risk of anaphylaxis   
Check the previous injection site Adverse reaction outcome 
assessment 
  
Check the patient is in the appropriate 
position for administration of the injection 
for the site selected 
To support accuracy of  
location of muscle group and 
prevent discomfort 
  




Human Factor Error Risk  
Reduction Checklist for the 
Administration of a 
Long-Acting Intramuscular 
Injection 














Landmark and locate the injection site Prevents damage to nerve 
structures and blood vessels 
  
Clean the injection site if required. If 
using an alcohol-based swab, allow to 
dry for 60 seconds 
Reduces discomfort   
Use Z-track technique and keep the 
graduation markings on the 
syringe barrel visible 
Prevents discomfort and back 
flow of medication. If the needle 
and syringe become 
disconnected, it will be impossible 
to establish how much medication 
has been administered 
  
Insert needle and check for  
aspirate before proceeding (only  
necessary for the dorsogluteal site) 
Prevents administration into the 
bloodstream 
  
Injection should be given at a rate of 1 ml in 
10 seconds 
To allow the muscle fibres to 
expand to absorb the solution. 
Reduces the risk of syringe barrel 
‘locking’ and incomplete 
administration of the dose 
  
Retract or remove the needle from the 
patient 10 seconds after 
administration of the injection 
To allow the medication to diffuse 
at the point of entry 
  
Dispose of all sharps immediately following 
withdrawal from patient 
Minimises the risk of blood-borne 
virus transmission and 
contamination 
  
Dispose of all equipment safely and 
appropriately 
Reduces the risk of 
contamination and inoculation 
injury 
  
Observe the patient for deviations from 
expected outcomes during 
the procedure 
Allows rapid action by assessing for 
any untoward event and 
formulating a plan of care through 
intervening with speed. Compliance 
with risk management processes 
and reporting of untoward events 
 
  
The administration record must be signed 
and all necessary clinical recording made 
Accurate recording of the 
procedure and any deviations 
from the norm is essential 
  
Advise the patient when to get in touch 
and who to contact if they 
have concerns about their wellbeing 
following the administration and ensure a 
patient information leaflet is given for 
reference 
The patient has all the necessary 
information to make continued 
healthcare decisions 
  






             Appendix 9: An Audit Tool for Oil-based Depot and Other Long-Acting Intramuscular Antipsychotic Injections  
 
 


























 Non-Adherence:  
 



















The registered practitioner 
has access to evidence 
based, up-to-date  
procedural guidance/ good 
practice documents that 
describe safe practice for 
prescribing, preparing, 
administering and monitoring 
injectable medicines 
100% Intranet clinical policies 
and procedures 
Clinical policies and 
procedures folder 
Good practice data base 
National Patient Safety 
Agency information 
Policy and procedure 
approval date from local 
sign-off committee 








All registered practitioners 
who are expected to  
administer an injectable 
medicine have received 
training within the clinical 
team 
100% Training data base None 
identified 







































Responsibility &  
Timescale for 
Completion 
   





Patient’s full name is  
correctly entered onto 









  identified 
   
 
4 





  identified 
   
 
5 
The prescription is legible 100% Prescription/administration 
document 
None 
  identified 
   
 
6 





  identified 








Pharmacy signatory records 
for registered practitioners 
None 
  identified 
   
 
8 
Dosage and frequency 




  identified 








The antipsychotic is  
administered as prescribed 
with 
respect to 







change and is 
recorded in the 


















































A physical healthcare  
assessment has been 
undertaken in the last year 
100% Medical/nursing notes None  
identified 





It has been documented 
that joint decision making 
between the prescriber and 
patient regarding the  
antipsychotic has taken place 
100% Medical/nursing notes None  
identified 





Documented evidence of 
information on this 
treatment having been 
given to the patient prior 
to its prescription 
100% Medical/nursing notes None 
    identified 




If the patient lacks capacity 
the decision is discussed 
with the carer or advocate 
100% Medical/nursing notes None  
identified 




Adherence has been 
discussed and recorded at the 
point of prescription 









The patient has been asked 
whether they would prefer a 
long-acting injection to an oral 
formulation by the prescriber 








Side effects have been 
assessed and recorded in the 
notes within the last six 
months 



















































The antipsychotic is 
 prescribed within the 
standard dosage range and 
frequency interval 
in accordance with 




















If the antipsychotic is pre- 
scribed outside 
recommended BNF/SmPC 
limits there is a clearly 
recorded 
clinical rationale for this 
decision 









Therapeutic response to 
treatment is recorded at 
clinical reviews at least 3 
monthly 




   
 
20 
The patient has undergone a 
clinical review within the 
last 3 months 
100% Medical/nursing notes None 
 identified 




A clinical review has 
involved the patient’s carer 
within the last 3 months 
where applicable 


















































Patients prescribed an oil- 
based depot long-acting 
intramuscular antipsychotic 
injection for the first time 
are given a test dose of the 
preparation to assess for 
tolerability 













Consent for administrating 
the injection has been  
obtained from the patient 
and is documented in the 
notes when each injection is 
administered 
100% Medical/nursing notes None  
identified 






The reason for  
administering the injection is 
documented in the patient’s 
notes by the nurse 
performing the procedure 
after each injection is 
administered 
100% Medical/nursing notes None  
identified 






Where the patient lacks 
capacity to give informed 
consent to receive the  
injection, the reason why the 
registered nurse believes 
the intervention to be in the 
best interests of the  
individual is recorded in the 
notes 
100% Medical/nursing notes None  
identified 





































Responsibility &  
Timescale for 
Completion 









An evaluation of the  




Reference has been made to: 
c) Observation for swelling 
d) Pain 
e) Inflammation  
f) Infection 
g) Tissue viability damage 
h) Patient concerns 
100% Medical/nursing notes None  
identified 









At the time of each injection 
the following is recorded: 
Name of antipsychotic 
Date of administration 
Time of administration 
Dose administered 
Injection site 
Side in which it was given (L) 
or (R)? (cross  
  reference with prescription/ 
administration  
document) 










The injection site is rotated 
after each administration 










Side effects of the previous 
injection have been assessed 
and documented in the notes 
100% Medical/nursing notes None  
identified 
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